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ABSTRACT 
 The purpose of this study was to determine the effects of chronic estrogen 
supplementation on NPY neurotransmission in gastrocnemius first-order arterioles (G1A) 
of adult female rats.  Female rats (4 mo; n = 30) were ovariectomized (OVX) with a 
subset (n = 15) receiving an estrogen pellet (OVE; 17β-estradiol (4μg / day)).  Following 
conclusion of the treatment phase (8 weeks), red G1A were excised, placed in a 
physiological saline solution (PSS) bath, and cannulated with micropipettes connected to 
albumin reservoirs.  A sampling port was placed immediately below the vessel to assess 
NPY overflow.  The contralateral red G1A was homogenized in PSS for dipeptidyl 
peptidase IV (DPPIV) assay.  NPY-mediated vasoconstriction via a Y1-agonist, 
[Leu31Pro34]NPY, decreased vessel diameter 44.54 ± 3.95% as compared to baseline; 
however, there were no group differences in EC50 (OVE: -8.97 ± 0.36; OVX: -8.72 ± 
0.20 log M [Leu31Pro34]NPY) or slope (OVE: -1.37 ± 0.38; OVX: -1.64 ± 0.31 % 
baseline / log M [Leu31Pro34]NPY).  NPY did not potentiate norepinephrine-mediated 
vasoconstriction.  NPY overflow experienced a slight increase following field 
stimulation, and significantly increased (p < 0.05) over control conditions in the presence 
of a DPPIV inhibitor (diprotin A).  Estrogen status did not affect DPPIV activity.  These 
data suggest that NPY can induce a moderate decrease in vessel diameter in skeletal 
muscle G1A, and DPPIV is active in mitigating NPY overflow in young adult female 
rats.  Chronic estrogen supplementation did not influence NPY vasoconstriction, 
overflow, or its enzymatic breakdown in skeletal muscle G1A.   
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INTRODUCTION 
The regulation of blood flow throughout the body is a process that utilizes local 
and systemic control mechanisms to ensure that metabolic demands are fulfilled while, at 
the same time, maintaining adequate blood pressure for the greater cardiovascular 
system.  The local control mechanisms of the vasculature consist of a finely tuned 
network of chemical processes that originate primarily from within the endothelium, 
whereas the systemic control lies within sympathetic innervations in addition to the 
endocrine stimuli in the blood.  It is a coordinated response between these loci that 
produces constant change in blood vessel diameter, which ensures normal function of 
biological processes. 
The neural control of blood vessel diameter is attributed to the sympathetic 
nervous system.  These sympathetic nerves arise from the spinal cord as pre-junctional 
nerves, synapse to the post-junctional nerve, and traverse across the blood vessel’s 
adventitial surface (Guyton & Hall, 2006).  Norepinephrine, adenosine triphosphate 
(ATP), and neuropeptide Y (NPY) are the primary neurotransmitters responsible for 
propagating the neural response from the sympathetic end terminal to the blood vessel.  
These neurotransmitters work in a coordinated fashion, each possessing their own degree 
of direct influence on the vessel while also modulating other chemical processes 
simultaneously.  There is evidence to suggest that sympathetic neurotransmission is not 
uniform between the sexes (Jackson, Milne, Noble, & Shoemaker, 2005a, 2005b).  
Females may possess more, or less, responsiveness to specific chemical mediators within 
the sympathetic triad.  These differences can be observed in neurotransmitter release, 
receptor function/activity, enzymatic activity, and cellular signaling. 
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Neuropeptide Y is found in vascular beds throughout the body, and it possesses 
many of the same direct and indirect actions as norepinephrine and ATP.  Neuropeptide 
Y is a potent vasoconstrictor, yet its role in vasoconstriction may be more relevant in 
small caliber vessels such as arterioles (Joshua, 1991; Kim, Duran, Kobayashi, Daniels, 
& Duran, 1994; Macho, Perez, Huidobro-Toro, & Domenech, 1989; Pernow, 1989) as 
opposed to large conduit vessels, which exhibit little to no responsiveness to NPY 
(Grundemar & Hogestatt, 1992; Tsurumaki, Honglan, & Higuchi, 2003; Wahlestedt, 
Yanaihara, & Hakanson, 1986).  Neuropeptide Y can elicit a 2- to 4-fold potentiation of 
vasoconstriction to norepinephrine in most vascular beds (Abel & Han, 1989; Prieto, 
Benedito, Simonsen, & Nyborg, 1991).  It is plausible that this mechanism is involved 
during low levels of sympathetic activation as potentiation is observed at nanomolar 
concentrations of both NPY and norepinephrine.  Neuropeptide Y autoregulates its own 
release as well as modulates the release of norepinephrine and ATP (Lundberg & Stjarne, 
1984; Ohhashi & Jacobowitz, 1983; Stjarne, Lundberg, & Astrand, 1986), thus NPY is 
intimately involved in all facets of sympathetic vasocontrol. 
 The beneficial effects of 17β-estradiol, herein referred to as estrogen, have been 
well documented with the most notable being the activation of endothelial nitric oxide 
synthase (eNOS) (Moriarty, Kim, & Bender, 2006).  This provides a secondary stimulus 
for the generation of nitric oxide, the first being luminal shear stress, which is a direct 
stimulus for vasodilation.  Estrogen modulates sympathetic neurite branching in uterine 
arteries, possibly due to direct actions on nerve growth factors such as brain derived 
neurotrophic factor (Krizsan-Agbas, Pedchenko, Hasan, & Smith, 2003).  A decrease in 
neurite density across the blood vessel would mitigate the degree of sympathetic 
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influence.  The cyclical neuritogenesis and neurite degeneration as influenced by estrogen 
throughout estrous is an example of how estrogen can impact the resultant magnitude of 
sympathetic neurotransmission.  A recent study found postmenopausal women to have 
higher concentrations of NPY within uterine arteries as compared to premenopausal 
women (Di Carlo, et al., 2007).  This information along with increased protease activity 
in young females as compared to males (Jackson, et al., 2005b) suggests that estrogen 
may play a role in sympathetic neurotransmission, but the full scope of that role remains 
to be fully understood. 
There is a disparity in the vascular responses to NPY between males and females 
with much of the differences attributed to total NPY content, the type of receptor 
expressed, and the activity of enzymes that breakdown NPY (Jackson, et al., 2005a, 
2005b).  Estrogen may be the underlying mechanism in the increase in NPY content in 
the reproductive vasculature following menopause, and it may be responsible, in part, to 
the differences observed in NPY neurotransmission in large conduit vessels.  There is a 
paucity of literature examining the actions of NPY in sympathetic neurotransmission of 
skeletal muscle, small caliber resistance vessels.  This level of the vasculature is of 
greater significance as it is at this level where the majority of regulatory control occurs 
with respect to systemic blood pressure (Segal, 2005).  The resistance vasculature is also 
affected in pathophysiological conditions such as peripheral arterial disease and diabetes 
(Cersosimo & DeFronzo, 2006), therefore the need for further study is clearly indicated. 
The specific aim of the proposed study is to examine the influence of estrogen on 
NPY release, post-junctional receptor activity, and enzymatic activity of proteases that 
degrade NPY.  It is my belief that estrogen will mitigate the overall stimulus of NPY in 
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the resistance vessels.  These results may explain a portion of the vascular changes that 
occur in response to the disruption of normal estrogen concentrations during menopause 
and beyond.  In addition, these results may elucidate yet another mechanism of estrogen’s 
cardioprotective function in the vasculature. 
Primary Aim:  To determine the effects of chronic estrogen supplementation on NPY 
release, receptor activity, and breakdown in gastrocnemius first-order arterioles. 
Hypotheses 
1. NPY release following field stimulation will decrease with chronic estrogen 
supplementation in gastrocnemius first-order arterioles. 
2. Chronic estrogen supplementation will decrease the amount of vasoconstriction in 
response to NPY administration in gastrocnemius first-order arterioles. 
3. Chronic estrogen supplementation will decrease the extent at which NPY potentiates 
adrenergic vasoconstriction in gastrocnemius first-order arterioles. 
4. DPPIV activity will be greater in gastrocnemius first-order arterioles with chronic 
estrogen supplementation. 
Limitations 
1. Arteriole size was not included in the statistical analysis of the DPPIV activity assay 
due to the sample medium’s interference with the kit components of the protein assay. 
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REVIEW OF LITERATURE 
Neuropeptide Y (NPY) is a 36-amino acid polypeptide that is widely expressed 
throughout the central and peripheral nervous systems.  Neuropeptide Y exhibits 
neuroendocrine function in the pituitary and hypothalamus, possessing various levels of 
influence on releasing hormones involved in satiety, reproduction, and development.  
Neuropeptide Y also acts as a neurotransmitter in central and peripheral nervous tissue 
owing to its functional duality in the body, and it is in this latter role that NPY exerts a 
level of influence over vascular regulation. 
NPY Structure and Synthesis 
 A family of polypeptides characterized by a tyrosine residue at the C-terminus 
was discovered in 1980 by Tatemoto and Mutt (1980).  Peptide YY and peptide histidine 
isoleucine were observed in the gut region with putative influence on pancreatic secretion 
(Jensen, Tatemoto, Mutt, Lemp, & Gardner, 1981; Tatemoto, 1982a).  A polypeptide was 
also observed in the brain, but it was thought to be peptide YY due to its characteristic N- 
and C-terminus tyrosine residues (Tatemoto, 1982a).  However, while sharing substantial 
sequence homology with peptide YY, the brain polypeptide was not identical (Tatemoto, 
1982b).  Thus, the brain polypeptide was designated as a novel neuropeptide, 
neuropeptide Y (Tatemoto, Carlquist, & Mutt, 1982).  In addition to sequence homology 
with peptide YY (67%), NPY is structurally similar to another gut peptide, pancreatic 
polypeptide (50%) (see Table 1) (Takeuchi & Yamada, 1985; Tatemoto, 1982b; 
Tatemoto, et al., 1988).  The gene that encodes NPY is found on chromosome 7 (7pter-
q22) (Takeuchi, et al., 1986), while the gene for pancreatic polypeptide is located on 
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chromosome 17.  The difference in chromosomal location for peptides of the same family 
could be attributed to evolutionary genetic translocation (Takeuchi, et al., 1986). 
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Table 1 
Amino Acid Sequences of NPY, Peptide YY, and Pancreatic Polypeptide 
 
Peptide 
 
Amino Acid Sequence 
 
NPY 
 
Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-
Ala-Glu- 
Asp-Met-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-
Asn-Leu- 
Ile-Thr-Arg-Gln-Arg-Tyr-NH2 
 
 
Peptide YY 
 
Tyr-Pro-Ile-Lys-Pro-Glu-Ala-Pro-Gly-Glu-Asp-Ala-Ser-
Pro-Glu- 
Glu-Leu-Asn-Arg-Tyr-Tyr-Ala-Ser-Leu-Arg-His-Tyr-Leu-
Asn- 
Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH2 
 
 
Pancreatic Polypeptide 
 
Ala-Pro-Leu-Glu-Pro-Val-Tyr-Pro-Gly-Asp-Asn-Ala-Thr-
Pro- 
Glu-Gln-Met-Ala-Gln-Tyr-Ala-Ala-Asp-Leu-Arg-Arg-Tyr-
Ile- 
Asn-Met-Leu-Thr-Arg-Pro-Arg-Tyr-NH2 
 
Note. Amino acids underlined are in the same sequential position as the corresponding 
amino acid in NPY; amino acids in bold are unique to that specific peptide. 
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Transcription and translation.  Prepro-NPY consists of a 97 amino-acid chain 
with a 28 amino acid signal peptide, followed by the expressed 36 amino acid peptide 
(NPY) (Minth, Bloom, Polak, & Dixon, 1984).  A polymorphism in the signal peptide 
(Leu7Pro) may influence translocation of prepro-NPY to the endoplasmic reticulum, 
post-translational modifications, and the expression of mature NPY (Kallio, et al., 2001).  
This polymorphism has been linked to hypercholesteremia and atherosclerosis in some 
populations (Karvonen, et al., 2000; Niskanen, et al., 2000).  Kaipio, Kallio, and Pesonen 
(2009) observed premature apoptosis and decreased angiogenesis in response to vascular 
endothelial growth factor in human umbilical vascular endothelial cells that possessed 
this polymorphism, which would be an indicator of endothelial dysfunction.  However, 
this polymorphism has also been associated with decreased free fatty acids and insulin 
concentrations during exercise (Kallio, et al., 2001).  While the increase in NPY appears 
to accompany this polymorphism, it is difficult to surmise a negative or positive 
relationship in cardiovascular profile.  The amino acid chain that follows expressed NPY, 
C-flanking Peptide Of Neuropeptide Y (CPON), may have physiological function (Allen, 
Polak, & Bloom, 1985).  Immunoreactivity to CPON was detected in the heart, adrenal 
glands, and kidney.  In the brain, CPON immunoreactivity was detected in the 
hypothalamus, striatum, hippocampus, frontal cortex, and the brain stem.  While CPON 
immunoreactivity appears to mirror NPY concentrations in certain tissues, a 
physiologically relevant function for CPON has not been identified.   
NPY Locations 
 Brain.  NPY is the most abundant peptide of the brain (Adrian, et al., 1983) with 
NPY immunoreactivity detected at greatest concentrations in the deep layers of the brain 
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and brain stem (Y. S. Allen, et al., 1983; Sawchenko, et al., 1985).  In the limbic system, 
NPY immunoreactivity was present in the arcuate and paraventricular nuclei of the 
hypothalamus (Lundberg, Terenius, Hokfelt, & Tatemoto, 1984), the pineal gland, and 
the pituitary gland (Chronwall, et al., 1985).  Neuropeptide Y immunoreactivity was also 
found in the hippocampus and the dentate gyrus.  In the brain stem, cell bodies with NPY 
immunoreactivity were observed in the periaqueductal gray region, and to a lesser extent, 
the locus coeruleus, the nuclei of the tractus solitarius (Lundberg, Terenius, et al., 1984), 
and the superficial laminae of the trigeminal nucleus.  In the medulla oblongata, NPY 
immunoreactivity was abundant in the raphe nuclei of the reticular formation and the 
dorsal motor nucleus of the vagus (Hokfelt, et al., 1983).  In the basal ganglia, high 
concentrations of NPY immunoreactivity were found in the caudate nucleus and putamen 
(Adrian, et al., 1983).  Hypothalamic NPY is released at circadian intervals with the 
greatest release occurring in the morning (7:00am) followed by a gradual decline 
throughout the day (Nicholson, et al., 1983).   
 Neuropeptide Y can be found in NPYergic (Bai, et al., 1985), adrenergic, and 
GABAergic (Hendry, et al., 1984) neurons within the brain.  The NPYergic neurons 
arising from the arcuate nucleus contain a rich supply of NPY (Bai, et al., 1985).  
Removal of the arcuate nucleus resulted in a steep decline in NPY immunoreactivity 
suggesting that this is the primary origin of NPY immunoreactivity found in the brain.  
Neuropeptide Y is transported in A1-3 (Bai, et al., 1985; Everitt, et al., 1984), A4-8, A10, 
A12, A14-15 (Everitt, et al., 1984), and C1-3 (Everitt, et al., 1984; Sawchenko, et al., 1985) 
adrenergic neurons.  Neuropeptide Y immunoreactivity co-localizes with norepinephrine 
(A1-2, A4, A6) and epinephrine (C1-2) in adrenergic neurons, however trace amounts of 
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NPY immunoreactivity have been observed in the absence of catecholamines (A5, A7, A8-
10, A12, A14-15) (Everitt, et al., 1984).  Since GABAergic (λ-aminobutyric acid) neurons 
participate in inhibitory stimuli, NPY found in GABAergic neurons may play a role in 
facilitating the actions of this neuronal type (Hendry, et al., 1984). 
 In the brain, NPY exhibits neuroendocrine behavior by modulating the release of 
hormones involved in protein synthesis, cell growth, reproduction, and eating behavior 
(Clark, Kalra, Crowley, & Kalra, 1984; J. K. McDonald, Lumpkin, Samson, & McCann, 
1985).  NPY also has cerebrovascular actions, however this will be discussed in 
subsequent sections and will receive no further mention here.  Neuropeptide Y is a potent 
stimulus for the feeding response in animal models.  Intraventricular injection of NPY 
resulted in an increased feeding response, and this response was 3-fold greater than the 
response elicited by pancreatic polypeptide (Clark, et al., 1984).  In a separate study by 
Stanley, Daniel, Chin, and Leibowitz (1985), carbohydrate was the preferred 
macronutrient following intraventricular injection with smaller differences between 
control and experimental trials in fat and protein consumption. 
 Neuropeptide Y possesses stimulatory effects on pituitary release of luteinizing 
hormone (Kalra & Crowley, 1984; Kerkerian, Guy, Lefevre, & Pelletier, 1985; J. K. 
McDonald, et al., 1985).  In ovariectomized rats with estrogen/progesterone 
supplementation, intraventricular injection of low concentrations of NPY (0.1-2.0μg) 
resulted in a marked increase in luteinizing hormone concentrations 10 minutes following 
application (Kalra & Crowley, 1984).  Luteinizing hormone-releasing hormone 
concentrations tend to rise and fall in concert with NPY concentrations, suggesting a 
modulatory effect for NPY on luteinizing hormone-releasing hormone (Crowley, Tessel, 
 11 
 
O'Donohue, Adler, & Kalra, 1985).  Progesterone administration causes a substantial, yet 
transient, increase in NPY and luteinizing hormone-releasing hormone within the median 
eminence followed by a gradual decline with a concurrent rise in luteinizing hormone 
concentrations (Crowley, et al., 1985; Kalra & Crowley, 1984).  This suggests that NPY 
release within the hypothalamus is sensitive to progesterone, and that NPY may possibly 
modulate the effects of luteinizing hormone-releasing hormone and subsequent 
luteinizing hormone release (Crowley, et al., 1985).  Neuropeptide Y may act directly on 
the anterior pituitary to stimulate the release of luteinizing hormone and follicle-
stimulating hormone (FSH) (J. K. McDonald, et al., 1985), however the significance of 
this mechanism in vivo is unknown.  Progressively larger concentrations of NPY (2-5μg) 
depressed circulating concentrations of growth hormone (GH) (J. K. McDonald, et al., 
1985). 
 Adrenal gland.  Neuropeptide Y is found in the adrenal glands of many animals 
with the greatest proportion found in the adrenal medulla (Varndell, Polak, Allen, 
Terenghi, & Bloom, 1984).  There is considerable variability across species in adrenal 
NPY content with some animals such as mice expressing significant amounts 
(1244pM/g) and other animals such as dogs expressing very little (68pM/g) (Allen, 
Adrian, Polak, & Bloom, 1983).  In the adrenal cortex, NPY immunoreactivity exists in 
the varicose nerve fibers that span the zona reticularis and the subcapsular cortical area 
(Varndell, et al., 1984).  In the adrenal medulla, NPY co-localizes with norepinephrine, 
but not epinephrine, in small (90-120nm) chromaffin granules. 
 Peripheral vasculature and smooth muscle.  Neuropeptide Y is widely 
expressed in perivascular nerve fibers that form plexuses across blood vessels (Grasby, 
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Morris, & Segal, 1999) and terminate at the adventitial-tunica media border (Fleming, 
Gibbins, Morris, & Gannon, 1989).  Neuropeptide Y or NPY immunoreactivity has been 
detected in the gut (Ekblad, Ekelund, Graffner, Hakanson, & Sundler, 1985; Lundberg, 
Terenius, Hokfelt, & Goldstein, 1983; Sundler, Moghimzadeh, Hakanson, Ekelund, & 
Emson, 1983), ear (Hieble, Ruffolo, & Daly, 1988), uvea (Terenghi, et al., 1983), 
throughout the female and male reproductive anatomy (Lundberg, et al., 1983; Owman, 
et al., 1986; Stjernquist, et al., 1983), kidney (Ballesta, Polak, Allen, & Bloom, 1984), 
respiratory tract (Uddman, Sundler, & Emson, 1984), heart (Gu, et al., 1984), thyroid 
gland (Grunditz, Hakanson, Rerup, Sundler, & Uddman, 1984), spleen (Lundberg, et al., 
1983), omentum (Edvinsson, et al., 1985), skin (Lundberg, et al., 1983), and sweat glands 
(Tainio, Vaalasti, & Rechardt, 1986).  Neuropeptide Y is found in a variety of 
nonvascular smooth muscle such as vas deferens (Fried, Terenius, Hokfelt, & Goldstein, 
1985; Lundberg, et al., 1983), intestine (Sundler, et al., 1983), lung (Lundberg, et al., 
1983), and eye (J. M. Allen, G. P. McGregor, et al., 1983). 
 Other nonvascular sites.  Neuropeptide Y is also found in the submucosal layers 
of the stomach (Ekblad, et al., 1985), prostate gland, submandibular gland (Lundberg, et 
al., 1983), fallopian tube, uterus (Owman, et al., 1986), and thyroid gland (Grunditz, et 
al., 1984). 
NPY Storage and Transport 
 Neuropeptide Y is co-stored along with norepinephrine in the large dense-cored 
vesicles (80-120nm) of adrenergic neurons (Ekblad, et al., 1984; Fleming, et al., 1989; 
Fried, Terenius, et al., 1985; Grasby, et al., 1999; Lundberg, et al., 1983; Tainio, et al., 
1986).  A 50:1 ratio of norepinephrine to NPY exists in these large vesicles, while no 
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NPY immunoreactivity is observed in the small-type (50nm) vesicles (Fried, Lundberg, 
& Theodorsson-Norheim, 1985; Fried, Terenius, et al., 1985).  Unlike norepinephrine, in 
which neurons have the enzymatic capability (tyrosine hydroxylase, dopamine  β-
hydroxylase) for synthesis within the sympathetic end terminal (Fried, Lundberg, et al., 
1985), NPY depends (9mm/hour) on axonal transport for reconstitution.  Therefore, the 
discrepancy in norepinephrine:NPY ratios can become more pronounced in distal 
sympathetic end terminals (Fried, Lundberg, et al., 1985).  Reserpine experiments, which 
deplete the neurotransmitter content of sympathetic end terminals, produced a rebound 
supracompensation of norepinephrine and dopamine  β-hydroxylase (160% and 140%, 
resp.) that was observed four days following reserpine administration (Dahlstrom, et al., 
1986).  In comparison, NPY experienced a slight decrease over time in addition to the 
acute decline (50%) that occurred following reserpine treatment (Dahlstrom, et al., 1986; 
Morris, Murphy, Furness, & Costa, 1986).  The disparity in reconstitution between NPY 
and norepinephrine supports the putative differences in neurotransmitter synthesis and 
transport. 
 Neuropeptide Y is also stored and released from chromaffin granules within the 
adrenal medulla, thus participating in the systemic pressor response along with 
norepinephrine and epinephrine (Lundberg, Fried, Pernow, & Theodorsson-Norheim, 
1986).  Upon adrenal activation, systemic concentrations of NPY can increase 2-fold over 
normal resting concentrations, while norepinephrine and epinephrine experience a greater 
increase in circulating concentrations (Lundberg, Fried, Pernow, & Theodorsson-
Norheim, 1986).  The larger increase in circulating catecholamines is, in part, attributed 
to larger stored concentrations within the adrenal medulla.  In the adrenal medulla of the 
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cat, NPY storage is 1:2000 to norepinephrine and 1:1500 to epinephrine (Lundberg, 
Fried, Pernow, & Theodorsson-Norheim, 1986).  However, NPY remains elevated in the 
circulation for a longer duration as compared to norepinephrine and epinephrine 
following a pressor stimulus. 
NPY Release from Peripheral Sympathetic Nerves 
 Action potentials propagated from the proximal post-junctional nerve result in 
fusion of the neurotransmitter-containing vesicles to the neural membrane at the synapse 
and neurotransmitter release via exocytosis.  As NPY is co-stored with norepinephrine in 
large dense-cored vesicles, NPY is also co-released with norepinephrine during the neural 
action potential (Lundberg, Martinsson, et al., 1985; Pernow, 1988).   
NPY Receptors and Vascular Actions 
  There are six known receptors for NPY, Y1-6 (Balasubramaniam, 1997), although 
only a few possess vascular actions (Wahlestedt, et al., 1990).  In vascular smooth 
muscle, the Y1 receptor is located at the cell membrane where it binds with complete 
NPY(1-36).  The Y1 receptor belongs to a class of G-protein coupled receptors, whereby it 
creates the cellular conditions for vasoconstriction.  The Y2 receptor is primarily located 
on the sympathetic end terminal although it can be found on vascular smooth muscle in 
some vascular beds (Tessel, Miller, Misse, Dong, & Doughty, 1993a, 1993b).  However, 
unlike the Y1 receptor, the Y2 receptor is capable of binding C-truncated fragments of 
NPY in addition to binding the full-length peptide. 
 Y1 receptor mechanisms.  The binding of NPY(1-36) to the Y1 receptor results in 
the dissociation of an inhibitory G protein, Gi, which inhibits adenylate cyclase activity 
and subsequent cyclic AMP (cAMP) production (Lobaugh & Blackshear, 1990; Reynolds 
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& Yokota, 1988).  Pertussis toxin, which blocks Gi signaling, abrogates the decrease in 
adenylate cyclase activity and subsequent vasoconstriction following NPY administration 
(Andriantsitohaina, Andre, & Stoclet, 1990; Morris, 1991).  The fact that pertussis toxin 
does not effect the contractile mechanisms of vascular smooth muscle suggests that Gi 
signaling is a primary mechanism behind NPY vasoconstriction (Morris, 1991).  While 
pertussis toxin virtually blocks vasoconstriction in small arterioles (Andriantsitohaina, et 
al., 1990), there is still vasoconstriction to NPY in larger vessels (Morris, 1991) even in 
the presence of pertussis toxin.  This would suggest that other cellular signaling 
mechanisms are involved following activation of the Y1 receptor.  Indeed, an increase in 
intracellular calcium follows Y1 activation in many vascular beds (Oshita, Kigoshi, & 
Muramatsu, 1989; Pernow & Lundberg, 1986; Shigeri & Fujimoto, 1993; Tessel, et al., 
1993b; Xiong, Bolzon, & Cheung, 1993).  Nifedipine, an L-type calcium channel 
blocker, is successful in blocking a portion of vasoconstriction caused through Y1 
activation (Tessel, et al., 1993b).  The L-type calcium channel is voltage sensitive, and is 
the primary mechanism behind calcium influx in response to cell depolarization of 
vascular smooth muscle.  In cerebral and internal carotid arteries, NPY increased vascular 
smooth muscle membrane potential 15mV above baseline values (Abel & Han, 1989).  
Neild (1987) observed depolarization (+16mV over baseline) of rat tail artery similar to 
the values observed by Abel and Han (1989).  The onset of depolarization was slow (5-10 
minutes post-application), and a correlation was observed between vasoconstriction and 
depolarization.  The depolarizing effect of NPY is independent of endothelial influences 
as endothelium removal did not alter the increases in membrane potential following NPY 
administration (Gustafsson & Nilsson, 1990). 
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 Vascular smooth muscle contraction can also be influenced by the release of 
calcium from intracellular storage sites.  The second messenger that is most associated 
with the release of intracellular calcium stores is inositol 1,4,5-triphosphate (IP3).  
Neurotransmitters that utilize IP3 as a second messenger (e.g. norepinephrine) are capable 
of producing substantial vasoconstriction.  In porcine aortic vascular smooth muscle, 
NPY administration did not directly increase IP, IP2, or IP3 concentrations, but NPY did 
potentiate angiotensin II-mediated vasoconstriction (Lobaugh & Blackshear, 1990).  NPY 
also increased norepinephrine-stimulated IP3 production in rat tail artery (Duckles & 
Buxton, 1994).  The ability of NPY to stimulate or influence the upstream enzyme for IP3 
production, phospholipase C, is equivocal.  Lobaugh and Blackshear (1990) concluded 
that phospholipase C activity was unaffected by NPY administration in cultured porcine 
aortic vascular smooth muscle cells.  The absence of changes in phospholipase C activity 
and IP3 production was unexpected as NPY increased intracellular calcium in an 
environment void of extracellular calcium.  This would suggest an internal store of 
calcium susceptible to NPY activation.  Shigeri, Nakajima, and Fujimoto (1995) observed 
nonsignificant increases in IP3 production in cultured porcine aortic smooth muscle cells.  
However, their experiments included inhibitors for the various phospholipase C isoforms 
to determine what, if any, isoforms were susceptible to NPY stimulation.  Experiments 
that inhibited phospholipase C-β abolished the increase in intracellular calcium following 
NPY administration.  Therefore, NPY likely potentiates IP3 production via activation of 
phospholipase C-β.  While a subsequent increase in IP3 production following NPY 
administration is not substantial, it would appear that this pathway is involved in NPY-
mediated vasoconstriction via release of calcium from intracellular stores. 
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 ATP-activated potassium channel currents decreased by 43% with NPY 
administration in rabbit mesenteric artery (Bonev & Nelson, 1996).  These channels are 
inhibited by protein kinase C , which is a downstream signal of phospholipase C.  Bonev 
and Nelson (1996) noted increases in ATP-activated potassium channel currents 
following inhibition of protein kinase C and phospholipase C activity during NPY 
stimulation, which would support the notion of phospholipase C activation following Y1 
stimulation.  The conglomeration of active second messengers in some tissues could be 
the result of heterodimeric complexes comprised of multiple receptor subtypes (Pons, et 
al., 2008).  These complexes consist of Y1 and Y5 subtypes, and have been classified as 
Gi/o subtype receptors.  This heterodimeric complex inhibits adenylate cyclase activity 
and stimulates phospholipase C activity, which inhibits (cAMP (protein kinase A)) and 
promotes (IP3, diacylglycerol (protein kinase C)) the respective second messengers 
associated with each enzyme.  Certainly, there is still debate as to the functional 
significance of such multi-receptor complexes in producing meaningful concentrations of 
IP3.  Regardless, the Y1 receptor is recognized as the post-junctional receptor for NPY 
responsible for stimulating vasoconstriction via activation of L-type and R-type (Pons, et 
al., 2008) calcium channels. 
 Y2 receptor mechanisms.  The Y2 receptor is primarily located on the 
sympathetic end terminal where it acts to inhibit NPY release in addition to the inhibition 
of adrenergic and purinergic neurotransmitters (Lundberg, Torssell, et al., 1985).  There 
are vascular beds, however, where Y2 receptors are expressed on the vascular smooth 
muscle (McAuley & Westfall, 1992).  As a pre-junctional receptor, Y2 is a Gi-protein 
coupled receptor where it exerts influence on cellular signaling by inhibiting both 
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adenylate cyclase activity and N-type calcium channels (R. L. McDonald, Vaughan, 
Beck-Sickinger, & Peers, 1995; Wahlestedt, et al., 1990).  Y2 receptors have a high 
affinity for the full length peptide (NPY(1-36)) in addition to the cleavage products, NPY(2-
36) and NPY(3-36), of aminopeptidase P and dipeptidyl peptidase IV, respectively.  Y2 
receptors also exhibit binding affinity for the full-length and truncated fragments of 
peptide YY and pancreatic polypeptide (Wahlestedt, et al., 1990). 
 Vascular actions.  Neuropeptide Y stimulates vasoconstriction in many vascular 
beds through Y1 and Y2 receptor mechanisms previously discussed.  In the cat spleen, 
NPY caused a dose-dependent increase in perfusion pressure (Lundberg, Anggard, 
Theodorsson-Norheim, & Pernow, 1984; Lundberg, Fried, Pernow, Theodorsson-
Norheim, & Anggard, 1986).  The vascular response had a slow onset with the increase in 
perfusion pressure manifesting 2-5 minutes following NPY administration.  The 
vasoconstriction to NPY can linger over time.  In this tissue, the increase in perfusion 
pressure persisted for 10 minutes following the initial increase (Lundberg, Anggard, et 
al., 1984).  Furthermore, the increase in perfusion pressure was impervious to α- or β-
adrenoceptor blockade.  In porcine spleen, an increase in NPY-like immunoreactivity 
following transmural stimulation occurred 2-5 minutes post-stimulation, and the 
concentration was 4-5 times greater with larger frequencies (20Hz) as compared to small 
frequencies (2Hz) (Lundberg, Rudehill, Sollevi, Theodorsson-Norheim, & Hamberger, 
1986).  In rabbit cerebral and internal carotid arteries, NPY produced vasoconstriction 
that was 21% and 79% to vasoconstriction produced by histamine and norepinephrine 
(Abel & Han, 1989).  Minute vasoconstriction following NPY administration was 
observed in internal maxillary artery (Lacroix, Stjarne, Anggard, & Lundberg, 1988).  In 
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human studies, forearm blood flow decreased during NPY administration in a dose-
dependent fashion.  A similar lag in response was observed in these studies (2 minutes 
between time of administration and changes in blow flow) as was the long-lasting effect 
(~15 minutes of vasoconstriction) (Clarke, et al., 1991).  In human saphenous vein, NPY 
produced a small amount of vasoconstriction (~ 28% of maximum contraction) (Luu, 
Chester, O'Neil, Tadjkarimi, & Yacoub, 1992).  Neuropeptide Y, along with 
norepinephrine, is an important neurotransmitter involved in stimulating reflex 
vasoconstrictor mechanisms in humans (Stephens, Saad, Bennett, Kosiba, & Johnson, 
2004).  During whole body cooling, Y1 receptor blockade significantly decreased reflex 
vasoconstriction, while Y1 plus α-adrenoceptor blockade abrogated reflex 
vasoconstriction entirely. 
 In some vascular beds, NPY fails to cause direct vasoconstriction, but it can 
potentiate the vasoconstriction caused by other neurotransmitters.  In rat tail artery, NPY 
had no direct vasoconstriction, but did potentiate vasoconstriction to transmural nerve 
stimulation (Vu, Budai, & Duckles, 1989).  Interestingly, NPY did not potentiate 
vasoconstriction to norepinephrine in this vessel, although it did increase the rate of 
contraction to norepinephrine as well as transmural nerve stimulation.  In rabbit cerebral 
and internal carotid arteries, NPY was capable of potentiating vasoconstriction to 
norepinephrine with no change in maximum vasoconstriction (Abel & Han, 1989).  In the 
perfused mesenteric vascular bed, NPY administration produced little vasoconstriction, 
but potentiated vasoconstriction to norepinephrine and α,β-methylene ATP (Han, et al., 
1998).  It was concluded that NPY is involved in 30% of the vasoconstriction to 
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sympathetic nerve stimulation at this level of the vasculature when taking into account 
the potentiation of vasoconstriction to other neurotransmitters. 
 The ability of NPY to stimulate vasoconstriction appears to increase as vessel 
diameter decreases, thus becoming more relevant at the level of the resistance 
vasculature.  In rabbit tenuissimus muscle arterioles, NPY was 10-fold more potent on a 
molar basis as compared to norepinephrine (Pernow, Ohlen, Hokfelt, Nilsson, & 
Lundberg, 1987).  The magnitude of vasoconstriction was identical (65% and 64%) 
between NPY and norepinephrine, respectively, in these vessels.  As was seen in the 
perfused spleen, vasoconstriction was long-lasting with constriction observed five 
minutes following application.  There was also a 2-3 minute lag in response between the 
initial time of administration and the first signs of vasoconstriction.  In rat cremaster 
muscle, NPY-mediated vasoconstriction was approximately 61%, 54%, and 18% of 
resting diameter in first-, second-, and third-order arterioles (Joshua, 1991).  In hamster 
cheek pouch microvessels, NPY decreased resting vessel diameter by 50% with a lag 
time of 5 minutes between administration and response, and a long-lasting response up to 
20 minutes (Kim, et al., 1994).  Neuropeptide Y-mediated vasoconstriction was 
unaffected by α-adrenoceptor blockade.  In human small arteries, NPY was capable of 
eliciting vasoconstriction equal in magnitude to that of norepinephrine (Pernow, 1989).  
While the effects of NPY in skeletal muscle arterioles are unknown, the present literature 
suggests a larger overall response to NPY at the arteriole level. 
Proteolytic Enzymes 
 Dipeptidyl peptidase IV.  Dipeptidyl peptidase IV is a proteolytic enzyme that 
cleaves off the tyrosine-proline residue yielding a C-truncated product, NPY(3-36) 
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(Mentlein, Dahms, Grandt, & Kruger, 1993; Mentlein & Roos, 1996).  Dipeptidyl 
peptidase IV has been identified in human umbilical vascular endothelial cells 
(Zukowska-Grojec, et al., 1998) and it also exists in a soluble form (CD26) (Durinx, et 
al., 2000).  Dipeptidyl peptidase IV activity plays a significant role in modulating NPY 
neurotransmission in females as inhibition results in a significant decrease in blood flow 
and vascular conductance in external iliac arteries (Jackson, et al., 2005b).  Similar 
results were observed in vasoconstriction experiments of the rat tail artery using 
peptidase inhibitors (Glenn, Krause, & Duckles, 1997).  Alternative pathways such as 
angiogenesis are directly influenced by dipeptidyl peptidase IV activity as NPY-mediated 
angiogenesis depends on the activation of Y2 receptors, which have binding affinity for 
C-truncated fragments of NPY.  While dipeptidyl peptidase IV appears to possess a 
greater role in female NPY neurotransmission, the mechanisms that underlie this larger 
role have yet to be elucidated. 
Vascular Effects of Estrogen 
 Estrogen has many direct and indirect effects on local blood flow and blood 
pressure with most effects pertaining to vessel dilation.  The primary mechanism is 
activation of endothelial nitric oxide synthase, which produces nitric oxide (cyclic GMP) 
resulting in vasodilation (Moriarty, et al., 2006).  Estrogen also ameliorates the 
accumulation of free radicals through increased activity of dismutases and peroxidases 
(Duckles, Krause, Stirone, & Procaccio, 2006; Vina, Borras, Gomez-Cabrera, & Orr, 
2006).  In addition to the vasodilating effects, estrogen attenuates endothelium-dependent 
mechanisms involved in vasoconstriction.  Cyclooxygenase products such as 
prostaglandin H that arise from endothelial cells can be depressed in arteries with 
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estrogen (Davidge & Zhang, 1998).  Other endothelium-derived vasoconstrictive 
products such as endothelin 1 and angiotensin II, through estrogen’s influence on 
angiotensin converting enzyme, decrease with estrogen (Miller & Duckles, 2008).   
 Estrogen receptors (ERα, ERβ) are expressed on adrenergic, cholinergic, and 
serotenergic  nerves (Vanderhorst, Gustafsson, & Ulfhake, 2005).  Removal of estrogen 
can lead to increases in circulating norepinephrine concentrations and increases in 
vascular resistance (Miller & Duckles, 2008).  Estrogen decreases both the expression of 
α-adrenergic receptors and the enzymes (tyrosine hydroxylase) responsible for the 
production of precursors to norepinephrine (Kaur, Janik, Isaacson, & Callahan, 2007; 
Miller & Duckles, 2008).  In rat tail artery segments, estrogen supplementation resulted 
in decreased force production to norepinephrine (Stice, Eiserich, & Knowlton, 2009).  
Krizsan-Agbas, Pedchenko, Hasan, and Smith (2003) concluded that estrogen modulates 
sympathetic activity in uterine tissue by influencing the expression of brain derived 
neurotrophic factor, which modulates neuritogenesis and neurite degradation.  This 
modulatory influence was recently extended to vascular tissue with estrogen 
supplementation decreasing nerve growth factor expression in extracerebral blood vessels 
in addition to the superior cervical ganglia (Kaur, et al., 2007).  The effects of estrogen on 
NPY neurotransmission in the vasculature have not been determined. 
 The effects of sex on NPY neurotransmission have received attention in large 
conduit vessels.  Females possess less Y1 receptor expression and total NPY content in 
the gastrocnemius muscle (whole tissue) than their male counterparts (Jackson, et al., 
2005a).  Females also experience little change in blood flow to Y1 receptor blockade in 
external iliac arteries as compared to males (Jackson, et al., 2005a).  A follow-up study 
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by this same group found Y2 receptor expression to be greater in the gastrocnemius 
muscle of females (Jackson, et al., 2005b).  Females had a decrease in vascular 
conductance and blood flow during Y2 blockade with a return to baseline levels following 
combined Y1-Y2 blockade.  In a separate group of females, inhibition of the proteolytic 
enzymes that target N-terminal amino acid residues of NPY (Tyr and Tyr-Pro) resulted in 
a decrease in blood flow and vascular conductance, which suggests that these enzymes 
are intimately involved in the modulation of NPY neurotransmission in females (Jackson, 
et al., 2005b).  This research lends credence to a sex difference in NPY 
neurotransmission, but the underlying mechanism or mechanisms responsible for these 
differences cannot be answered with the present data.  The work of Glenn, Krause, and 
Duckles (1997) suggests that sex steroids, in general, modulate NPY neurotransmission 
in females.  However, there was more potentiation of vasoconstriction to transmural 
nerve stimulation following NPY administration in control females as compared to 
ovariectomized animals.   This would run counter to what Jackson, Milne, Noble, and 
Shoemaker (2005b) observed with the decreased Y1 receptor activity in females as 
compared to males.  However, Glenn, Krause, and Duckles (1997) did note a greater 
inhibition in vasoconstriction to transmural nerve stimulation following Y2 receptor 
stimulation in control animals, which is consistent with the greater expression of Y2 
receptors observed in females (Jackson, et al., 2005b).  A weakness of the Glenn, Krause, 
and Duckles (1997) study was the inability to control estrogen concentrations.  While 
attempts were made to monitor the rat’s estrous cycle, the inherent fluctuation of estrogen 
in intact females increases the experimental variability (error).  Little research exists 
regarding estrogen’s impact on NPY neurotransmission in human subjects.  Di Carlo et 
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al. (2007) detected increases in total NPY content of uterine arteries from post-
menopausal women.  While estrogen was not controlled per se, these results would 
suggest a possible modulatory role for estrogen with regards to NPY neurotransmission. 
Purpose of Study 
 The purpose of this study is to examine the effects of chronic estrogen 
supplementation on NPY release, NPYergic receptor actions, modulation of adrenergic 
vasoconstriction, and proteolytic enzymes that act on NPY.  It is expected that chronic 
estrogen supplementation will decrease NPY release and Y1 receptor-mediated 
vasoconstriction.  The potentiation effect of NPY on adrenergic vasoconstriction is also 
expected to attenuate with chronic estrogen supplementation.  Lastly, normally active 
proteolytic enzymes that modulate NPY neurotransmission through enzymatic cleavage 
of N-terminal amino acid residues will become less active in animals without chronic 
estrogen supplementation.  The present results may possibly elucidate another 
mechanism of estrogen's direct effect on sympathetic neurotransmission via the 
modulation of NPY neurotransmission in skeletal muscle arterioles.  This would further 
substantiate estrogen's crucial role in maintaining normal cardiovascular dynamics within 
the peripheral circulation as well as revealing the physiological changes that occur in 
skeletal muscle arterioles in the absence of estrogen. 
Treatment and Experimental Rationale 
 Ovariectomy and chronic estrogen supplementation.  Estrogen impacts the 
cardiovascular system through acute (Moriarty, et al., 2006) and chronic mechanisms 
(LeBlanc, et al., 2009; Stice, et al., 2009).  Ovariectomy is a means to remove the 
variability caused by estrogen, but comparisons to intact animals are fraught with 
 25 
 
potential errors pertaining to the estrous cycle.  The estrous cycle of a F344 rat is 4-5 
days in duration with estrogen fluctuation ranging from approximately 70pg/ml during 
proestrous to concentrations as low as 15-20pg/ml during estrous (Haim, Shakhar, 
Rossene, Taylor, & Ben-Eliyahu, 2003).  Efforts to 'time' the cycle in this animal model 
would be tremendously difficult, if not impossible, due to the variable nature of the 
estrous cycle in this particular breed.  The only valid experimental alternative is to 
control estrogen concentrations by means of a secondary source.  The use of estrogen 
pellets (Innovative Research of America) to maintain an internally controlled 
environment is a popular and convenient method for experimental control for this type of 
treatment.  While treatment (supplementation) times may vary (Davidge & Zhang, 1998; 
Kaur, et al., 2007; LeBlanc, et al., 2009; Robbins, Mebane, Ball, Shaffer, & Ness, 2010; 
Stice, et al., 2009; Yao, et al., 2005; Zhang, Stewart, & Davidge, 2000), chronic changes 
in the vasculature can be observed within two weeks (Kaur, et al., 2007).  Haim et al. 
(2003) determined that a daily dose of .27µg/day would result in an estrogen plasma 
concentration of 34.6pg/ml, and a daily dose of 1.11 µg /day would results in an estrogen 
plasma concentration of 137.8pg/ml in F344 rats.  The study by LeBlanc et al. (2009) on 
F344 rats used a daily dose of 1.67µg /day, which produced an estrogen plasma 
concentration of 41pg/ml.  This work was relevant to the proposed project in that it 
employed microvessel analyses of arterioles.  Most importantly, the dose and length of 
time (6-8 weeks) of the study was sufficient in observing not only changes in protein 
expression, but also changes in vascular response to agonist/antagonist treatments.  In the 
proposed study, a dose of .25 mg / 60 days, will be used for the estrogen supplementation 
group, which has a delivery rate of 4.17 µg /day.  The treatment time will range from no 
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earlier than 6 weeks to no later than 8 weeks.  The serum estrogen concentrations 
(Estradiol EIA kit, Oxford Biomedical, Oxford, MI) and uterine weight will be used to 
verify estrogen status for each animal at the time of terminal experiment. 
 Microvessel preparation.  In vitro microvessel preparations provide the means to 
study the microvasculature in isolation.  This is a form of technical control thereby 
limiting confounding elements that are difficult to control otherwise (e.g. systemic 
influences).  Furthermore, this preparation is one of few viable options for the study of 
microvascular contraction and relaxation in this animal model.  Flow probes, which are 
commonly used to measure blood flow, have yet to be designed for vessels of this size 
(100-300μm).  Therefore, this apparatus is a viable and effective tool in measuring 
microvascular contraction and relaxation.  In this study, the amount of contraction will be 
determined through measurement of the vessel’s diameter using video calipers (Colorado 
Video 307A Horizontal Video Calipers, Boulder, CO), which will be referenced against 
baseline diameter measurements.  While vessel diameter is the measurable event, this 
variable is synonymous with vasoconstriction. 
 Field stimulation.  Neuropeptide Y release to field stimulation typically occurs at 
large frequencies (>20Hz), with little to no release observed at small frequencies (2-
20Hz) (Lundberg, Rudehill, et al., 1986).  This frequency-dependent characteristic of 
NPY could be attributed, in part, to the large, dense-cored vesicles where NPY is stored 
(Ekblad, et al., 1984; Fleming, et al., 1989; Fried, Terenius, et al., 1985; Grasby, et al., 
1999; Lundberg, et al., 1983; Tainio, et al., 1986).  Therefore, a large frequency (60Hz) 
will be utilized in the present study.  While this is a large frequency of stimulation, 
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instantaneous frequencies that exceed 50Hz have been recorded in sympathetic 
vasoconstrictor nerves (Macefield, Wallin, & Vallbo, 1994). 
 Gastrocnemius first-order arteriole.  Two (red and white) gastrocnemius first-
order arterioles are downstream of the gastrocnemius feed artery.  The red arteriole 
supplies blood to the medial gastrocnemius, which is more oxidative than the lateral 
gastrocnemius.  Therefore, the red arteriole will be used in this study.  As a resistance 
vessel, the arteriole expresses a diverse array of adrenergic (Pernow, et al., 1987), 
NPYergic (Matsuda, Brumovsky, Kopp, Pedrazzini, & Hokfelt, 2002), and purinergic 
(Matsuura, Saino, & Satoh, 2004) receptors making it an ideal vessel for the study of 
sympathetic neurotransmission.  Furthermore, blood pressure is maintained at the level of 
the resistance vasculature, which is capable of accommodating a 100-fold increase in 
blood flow during periods of maximal oxygen demand (Segal, 2005). 
 Joshua (1991) observed increases in first-order arteriole vasoconstriction 
following NPY administration by approximately 39%.  Macho et al. (1989) concluded 
coronary resistance vessels (arterioles) to be highly responsive to NPY with regards to 
vasoconstriction while noting little responsiveness in large conduit vessels.  Neuropeptide 
Y was 250-fold more potent than norepinephrine in these coronary arterioles.  While this 
research pertained to coronary arterioles, the available literature suggests an inverse 
relationship between vessel diameter and vessel responsiveness to NPY.  Dipeptidyl 
peptidase IV is also more active in the gastrocnemius first-order arteriole as compared to 
the femoral artery (unpublished data). 
 Cumulative concentration response curves.  Arteriole vasoconstriction to NPY 
has been achieved at nanomolar concentrations (10-11-10-7M) (Joshua, 1991; Kim, et al., 
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1994; Pernow, et al., 1987).  Therefore, this concentration range for NPY will be 
encompassed in the NPY concentration response curve performed in this proposal (10-11-
10-5M).  The potentiation of norepinephrine vasoconstriction can be elicited at nanomolar 
concentrations of NPY (10-9-10-7M) (Abel & Han, 1989; Hieble, et al., 1988; Prieto, et 
al., 1991; Small, Bolzon, & Cheung, 1992).  The greatest concentration (10-7M) of NPY 
associated with potentiation of vasoconstriction to norepinephrine will be used as it is the 
most oft reported concentration with measureable effects (Vu, et al., 1989). 
Preliminary Data 
 Neuropeptide Y release has been successfully measured in the gastrocnemius 
first-order arteriole using the proposed peptide enzyme immunoassay.  Figure 1 is NPY 
release during α2-adrenoceptor stimulation and inhibition (n=2).  The increase in NPY 
release following idozoxan (α2-adrenoceptor antagonist) is consistent with synergistic 
effects of adrenergic and NPYergic neurotransmission. 
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Figure 1.  The effects of α2-adrenoceptor blockade on NPY release following field 
stimulation (n = 2). NPY release was detectable using the proposed peptide enzyme 
immunoassay.
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Dipeptidyl peptidase IV has been successfully measured in the gastrocnemius 
first-order arteriole using the synthetic substrate, glycyl-L-proline-4-methoxy-2-
naphthylamide.  Figure 2 represents dipeptidyl peptidase IV activity in the femoral artery 
and gastrocnemius first-order arteriole (n=16).  Dipeptidyl peptidase IV activity is greater 
in the arteriole.  Figure 3 represents dipeptidyl peptidase IV activity in male and female 
gastrocnemius first-order arterioles (n=8). 
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Figure 2.  DPPIV activity of gastrocnemius first-
order arterioles (G1A: n = 16) and femoral 
arteries (FEM: n = 16).  DPPIV activity was 
assessed using the substrate, glycyl-L-proline-4-
methoxy-2-naphthylamide. Bars indicate mean ±
S.E.M.  * Significant difference from OVX (p < 
0.05).
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Figure 3.  DPPIV activity of male (n = 8) and 
female (n = 8) gastrocnemius first-order arterioles.  
Bars indicate mean ± S.E.M..
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METHODS 
Animal Model 
 The Fischer 344 rat (F344) exhibits neutral vascular physiology and is void of 
hypertensive or other inherent vascular pathological conditions that would preclude 
detailed vascular study (Harlan Laboratories, n.d.).  All female F344 rats will be 
ovariectomized with 15 rats receiving an estrogen pellet (N=30) (Innovative Research of 
America, Sarasota, FL) at the time of ovariectomy in order to maintain experimental 
control over systemic estrogen concentrations.  Animal behavior, food and water intake, 
appearance, and surgical incisions will be monitored for 10 days post-operatively.  
Records will be kept regarding surgical comments, animal condition, and drug 
administration (name, dose, route of administration).  Animals will be housed in 17" X 
10" X 7.5" cages.  A 75%/25% mixture of hardwood chip/wood pulp bedding will be 
used as bedding material.  Food and water will be provided ad libitum. 
Apparatus and Procedure 
Ovariectomy and Pellet (17β-Estradiol) Implantation 
 Female F344 rats (3-4 months of age) were anesthetized using 40mg/kg IP, 
sodium pentobarbital.  A ventral midline incision was made in the skin caudal to the 
border of the ribs and cephalad to the pubic symphysis.  A subcutaneous tunnel was made 
lateral to the skin incision and the muscles of the abdominal wall separated to allow 
access to the abdominal cavity.  Using forceps, the periovarian fat was grasped in order to 
lift and exteriorize the ovary.  The fallopian tube and the uterine horn distal to the ovary 
were clamped and the ovary removed by cutting above the clamped area.  Following 
removal of the ovary, the uterine horn was returned to the abdomen and the process 
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repeated for the second ovary.  The skin incision was closed using one or two sutures or 
wound clips. 
 In the chronic estrogen supplementation group, estrogen pellets (.25mg; 60 days) 
were delivered subcutaneously immediately following ovariectomy.  The pellet was 
implanted in the dorsoscapular region just behind the left ear above the shoulder using a 
10-gauge trochar. 
 The rats were treated with a topical antibiotic when necessary to prevent 
infection.  External sutures were removed 7-10 days following surgery.  Animals were 
housed for 6-8 weeks following ovariectomy to allow for the chronic vascular adaptations 
associated with estrogen to occur (LeBlanc, et al., 2009). 
Terminal Experiment 
 Six to eight weeks post-ovariectomy, the rats were administered a single IP dose 
of 0.5-0.8cc of 42.5mg/ml (71mg/kg to 113mg/kg) pentobarbital sodium to induce a deep 
plane of anesthesia.  Depth of anesthesia was determined by lack of response to toe 
pinching.  Following induction, arterioles were dissected out and removed.  Arterioles 
were cannulated with glass pipettes to measure vessel diameter.  The process of removing 
the arterioles took approximately 20 minutes.  Blood (5ml) was collected via cardiac 
puncture.  Blood samples were centrifuged for 3 minutes, the supernatant removed, and 
the serum stored at -80C.  Immediately following removal of the vessels, an intracardiac 
dose of pentobarbital and a pneumothorax was administered.  The uterus was removed, 
trimmed of connective tissue, and weighed.  
 Vessel chamber.  Arterioles were isolated in a refrigerated vessel chamber 
containing cold (4°C) Krebs-Ringer physiological saline solution (119mM NaCl, 4.7mM 
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KCl, 2.5mM CaCl2, 1.2mM MgSO4, 25mM NaHCO3, 1.2mM KH2PO4, 5.5mM glucose, 
2mM glycerol) (Pourageaud & De Mey, 1998) bubbled with 30% O2, 10% CO2, 60% N.  
Using 11-0 opthalmic suture, the arterioles were tied securely to micropipettes in a vessel 
chamber (Living Systems, Inc., Burlington, VT) and filled with Krebs-Ringer 
physiological saline solution (described above) containing 1% albumin (pH 7.4, 37°C) 
(Pourageaud & De Mey, 1998).  The bath was filled with Krebs-Ringer physiological 
saline solution (pH 7.4, 37°C) and transferred to the stage of an inverted microscope 
(Olympus (CKX41), Melville, NY).  Luminal diameter was monitored during 
equilibration and viability testing (described below) using video calipers (Colorado video 
307A Horizontal video calipers, Boulder, CO) and recorded on a computer.  The bath 
was gradually warmed and maintained at 37°C for the equilibration period.  
Micropipettes were connected to independent reservoir systems.  Luminal pressure was 
initially set at 60cm H2O, which is a pressure similar to normal in vivo pressure in 1A 
arterioles (Williams & Segal, 1993).  The bath solution was replaced every 15 minutes 
during equilibration.  Arterioles were considered viable if they constricted to 
phenylephrine (10-5M) by at least 10% and dilated by at least 20% to acetylcholine (10-
6M ) (Schneider, et al., 1994).  Maximum vasoconstriction (μm) was assessed by the 
average vasoconstriction produced by potassium chloride (80mM) prior to, and 
immediately following, that day's experiments.  The arteriole was washed out 5 times, 
and a calcium-free buffer was added to the bath to measure maximum arteriole dilation 
(μm). 
 Field Stimulation.  The arteriole was field stimulated using two platinum 
electrodes connected to an electrically isolated, constant current stimulator (Digitimer 
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(DS3), Welwyn Garden City, Hertfordshire, UK).  In our lab’s experience, field 
stimulation can be repeated up to four times without a loss of vascular tone. 
 Randomization.  The following series described below were randomized to 
minimize variability due time effects (i.e. the length of time the vessel is maintained in 
the microvessel bath).  The cumulative concentration response curves within Series 3 
were randomized to reduce sequence effects. 
 Series 1: NPY release to field stimulation.  The vessel received field stimulation 
(60Hz, 9mA, 7 impulses), followed by extraluminal sampling (~200µl) immediately after 
stimulation and 30 seconds post-stimulation.  Samples were flash-frozen with liquid 
nitrogen and stored at -80C.  At the conclusion of the first set of experiments, the vessel 
chamber was washed five times and allowed to equilibrate for 30 minutes before 
proceeding to the next set of experiments. 
 Series 2: Y1 post-junctional receptor sensitivity.  A cumulative concentration 
response curve using the Y1 specific agonist, [Leu31Pro34]NPY (Bachem, King of 
Prussia, PA), was performed (10-11-10-5M).  Doses were administered at five minute 
intervals.  Data was expressed as a percentage of maximum contraction (µm), percentage 
of baseline tension, EC50, and slope.  Data were analyzed using EC50 and slope.  At the 
conclusion of the second set of experiments, the vessel chamber was washed five times 
and allowed to equilibrate for 30 minutes before proceeding to the next set of 
experiments to avoid possible residual effects from the previous experiment. 
 Series 3: NPY potentiation of adrenergic vasoconstriction.  A cumulative 
concentration response curve for the α-adrenoceptor agonist, norepinephrine (10-11-10-
6M), was performed to determine adrenergic responsiveness of the vessel.  A 
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concentration of NPY(1-36)  (10-7M) capable of eliciting potentiation of norepinephrine 
vasoconstriction was added to the bath and allowed to incubate for five minutes.  A 
second cumulative concentration response curve for norepinephrine was performed to 
examine the potentiation effect of NPY on adrenergic vasoconstriction.  Data were 
expressed as a percentage of maximum contraction (µm), percentage of baseline tension, 
EC50, and slope.  Data were analyzed using EC50 and slope.  The vessel bath was 
washed out and the arteriole allowed to equilibrate as described above. 
 Series 4: DPPIV activity in gastrocnemius first-order arterioles.  The DPPIV 
inhibitor, diprotin A (1μM), was added to the bath and allowed to incubate for 20 
minutes.  The arteriole received field stimulation (60Hz, 9mA, 7 impulses), which was 
followed by extraluminal sampling (~200µl) immediately after stimulation and 30 
seconds post-stimulation.  Samples were flash-frozen with liquid nitrogen and stored at -
80C.  Upon completion of all animal experiments, samples were analyzed for NPY 
content using a peptide enzyme immunoassay (Bachem, King of Prussia, PA). 
 Arterioles from the contralateral gastrocnemius were homogenized in Krebs-
Ringer buffer, centrifuged, and the supernatant removed for DPPIV analysis.  DPPIV 
samples were flash-frozen with liquid nitrogen and stored at -80C.  Upon completion of 
all animal experiments, samples were analyzed for DPPIV and total protein content 
(Thermo Scientific, Rockford, IL) using spectrophotometric assay.  Serum concentrations 
of 17β-estradiol were determined using an estradiol immunoassay (Estradiol EIA kit, 
Oxford Biomedical, Oxford, MI). 
 Peptide enzyme immunoassay (EIA).  Vessel bath samples and EIA kit 
components were brought to room temperature before proceeding with NPY analysis.  
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The samples were placed in an antibody-coated, 96-well plate with provided standards.  
Primary antiserum and biotinylated peptide solutions were added and incubated for two 
hours at room temperature.  The samples were washed with an assay buffer and treated 
with streptavidin HRP solution and incubated for 60 minutes at room temperature.  
Following a second wash cycle, the substrate was added and the absorbance read at 
450nm (Bio-Tek Instruments Inc., Winooski, VT).  The concentration of NPY was 
determined using a normal curve.  The assay’s minimum detectable NPY concentration is 
2 to 3 pg per well or 0.06ng/ml. 
 Dipeptidyl peptidase IV assay.  Whole vessel homogenate samples were brought 
to room temperature.  The samples were then transferred to a 96-well plate and glycyl-L-
proline-4-methoxy-2-naphthylamide added (37).  The samples were incubated for 20 
minutes at 37°C and the reaction stopped using a citrate solution (100mM).  The 
fluorescent signal was read at 340 and 425nm by a FLX800 microplate reader.  DPPIV 
activity was defined as the activity that produces 1μM of 4-methoxy-2-napthalamine in 
one minute (Scharpe, et al., 1988). 
 Protein assay.  Whole vessel homogenate samples were brought to room 
temperature.  Samples (150µl) were transferred to a 96-well plate along with a working 
reagent (150 µl).  The plate was placed on a heating block (37°C) and allowed to incubate 
for 2 hours.  The plate was removed from the heating block to equilibrate to room 
temperature (~10min) before analysis.  Absorbance of a colorimetric signal was read at 
562nm.  Total protein content (µg/ml) was determined using a bovine serum albumin 
standard curve.  
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 17β-estradiol assay.   The organic phase was separated by vortexing the sample 
with ethyl ether.  The solvent was evaporated using a nitrogen stream, and the remaining 
residue was diluted in extraction buffer.  This sample was added to the microplate along 
with the enzyme conjugate, shaken, and incubated at room temperature for one hour.  
Following a wash cycle, the substrate was added with optimal color development 
(650nm) occurring within 30 minutes of administration.  Color development was 
inversely proportional to the concentration of estradiol. 
Statistical Design 
 It is prudent to minimize the number of statistical tests in order to decrease type I 
error rate.  Therefore, data of similar formats (e.g. cumulative concentration response 
curves and NPY release) were analyzed together when possible.  A multivariate analysis 
of variance (α=.05) was used to analyze the data from series 2 and 3.  The EC50 and 
slope were recorded for NPY, norepinephrine, and NPY+ norepinephrine cumulative 
concentration response curves.  A repeated measures design (α=.05) was used to assess 
differences in data from series 1 and 4.  NPY release (ng ml-1) with and without diprotin 
A (dipeptidyl peptidase IV inhibitor) was recorded at 0 seconds and 30 seconds post-field 
stimulation.  Greenhouse-Geisser’s epsilon was used as the criterion (O'Rourke, Hatcher, 
& Stepanski, 2005) for determining usage of either the univariate (ε > 0.75) or 
multivariate (ε < 0.75) case, where appropriate.  Dipeptidyl peptidase IV activity (second 
part of series 4) was analyzed using a one-way analysis of variance design (α=.05).   
 In our lab, we have previously detected differences in NPY release from 
gastrocnemius 1A arterioles.  Based on our prior work, we needed at least 12 animals to 
achieve power > .80 with α= .05 (Δ=1.83).  Previous analysis of dipeptidyl peptidase IV 
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activity in our lab did not include the vessel’s size in the determination of activity.  It was 
possible that total enzyme activity as determined by the amount of synthetic substrate 
converted to measureable product was a function of vessel size (i.e. there was more 
physical dipeptidyl peptidase IV protein in some experiments).  Consequently, the 
standard deviations were higher than desired, which for the present experiment, would 
have required a larger group size (n=21) in order to reach our desired power (>.80).  
Therefore, the protein assay was included in order to normalize the DPPIV activity with 
respect to the vessel’s size (total protein content).  Power calculations of subsequent 
enzyme assay (monoamine oxidase) results using protein quantification to normalize 
activity required a group size of 12 to meet a power of at least .80 with α= .05 (Δ=1.87).  
NPY-mediated vasoconstriction increases in magnitude as vessel diameter decreases.  
Joshua (1991) observed decreases of ~39±2% in first-order arteriole diameter following 
NPY administration.  This large effect yields a substantial degree of power (>.90).  Based 
on the aforementioned power calculations, this study utilized groups of 15 animals 
(N=30), which was deemed sufficient to detect group differences with power > .80; α= 
.05. 
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RESULTS AND DISCUSSION 
Results 
 Model assumptions for all statistical instruments were examined with follow-up 
measures performed when necessary.  Data considered essential for interpretation are 
included in the results.  Appendix A contains more detailed information regarding data 
organization, inclusion criteria for statistical analysis, and the handling of model 
assumptions. 
 A treatment duration of 8 weeks (56 days) was selected to allow for an adequate 
amount of exposure time to estrogen in order to detect the presence of physiological 
adaptations to chronic estrogen exposure.  The average treatment time (from OVX/OVE 
surgery to terminal experiment) was 55.76 ± 0.30 days, and the ages at the time of 
terminal experiment ranged from 158 days to 224 days.  The length of a terminal 
experiment was 6 hours; thus, a maximum of two experiments could be performed on any 
given day.  The small variation in treatment duration was due, in part, to conflicts that 
were either unavoidable or beyond control (meetings, equipment failure/damage).  A total 
of 35 rats were ovariectomized, while 17 rats also received the 17β-estradiol pellet.  The 
only death that occurred during the treatment phase was attributed to sodium 
pentobarbital overdose.  No rats exhibited signs or symptoms of surgical complications 
during the 10-day post-surgical observations, and there were no signs of infection or 
adverse conditions at the time of the terminal experiment.  
Animal Characteristics  
 Plasma estrogen concentrations were greater in rats with estrogen 
supplementation (OVE) as compared to rats without estrogen supplementation (OVX; 
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Figure 4: F (1, 9) = 7.67, p < 0.05).  The presence of estrogen can produce alterations in 
phenotype that are readily observable and easy to measure.  OVE exhibited less weight 
gain over the 8-week period (Figure 5: F (1, 32) = 47.05, p < 0.05) but had substantially 
larger uteri as opposed to OVX (Figure 6: F (1, 26) = 1812.17, p < 0.05).  Figure 7 
displays representative uteri from OVE (A and B) and OVX (C and D) rats.  The 
collective statistical effects of measurements related to estrogen supplementation were 
high (plasma estrogen: d = 1.68; body weight: d = 2.35; uterine weight: d = 16.09).  
These data suggest a significant difference in estrogen concentrations between OVE and 
OVX rats.   
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Figure 4.  Plasma estradiol concentration of 
OVX (n = 5) and OVE (n = 6) rats. Estrogen 
supplementation resulted  in an increase in plasma 
estradiol levels.  Bars indicate mean ± S.E.M.  
* Significant difference from OVX (p < 0.05).
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Figure 5.  Body weight of OVX (n = 17) and OVE 
(n = 17) rats. Estrogen supplementation resulted in 
significantly less body weight.  Bars indicate mean ±
S.E.M.  * Significant difference from OVX             
(p < 0.05).
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Figure 6.  Uterine weight of OVX (n = 14) and 
OVE (n = 14) rats. Estrogen supplementation 
resulted in significantly greater uterine weight.  Bars 
indicate mean ± S.E.M.  * Significant difference from 
OVX (p < 0.05).
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Figure 7.  Representative uteri from OVE (A and B) and OVX (C and D) rats.  
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Series 1: NPY release to field stimulation 
 Field stimulation at a high frequency is needed in order to facilitate the exocytosis 
of large dense-cored vesicles within the sympathetic nerve terminal (Lundberg, Pernow, 
Franco-Cereceda, & Rudehill, 1987).  NPY release increased from 0 to 30 seconds in 
OVX and OVE rats (Figure 8: F (1, 21) = 6.44, p < 0.05).  While OVX (n = 12) rats 
experienced slightly greater NPY release at 0 and 30 seconds, the release was not 
statistically different (F (1, 21) = 0.05, p < 0.83, D2 = 0.05) from OVE (n = 11). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 48 
 
Figure 8.  NPY release in gastrocnemius first-order arterioles of OVX (n 
= 12) and OVE (n = 11) rats.  NPY release was greater at 30s following field 
stimulation for all rats irrespective of estrogen status.  Bars indicate mean ±
S.E.M.  * Significant difference from 0s (p < 0.05).
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Series 2: Y1 post-junctional receptor sensitivity 
 This series was performed to determine the effects of long-term estrogen 
supplementation on Y1-receptor activity in skeletal muscle arterioles.  The Y1-receptor 
agonist, [Leu31Pro34]NPY, elicited a 45% decrease in vessel diameter of skeletal muscle 
arterioles.  Estrogen status did not affect the maximum amount of Y1-mediated 
vasoconstriction (F (1, 14) = 0.01, p = 0.91; d = 0.05) with OVE (55.07 ± 5.10%; n = 9) 
producing similar magnitudes of vasoconstriction to that observed in OVX (55.97 ± 
6.25%; n = 7).  The sensitivity of Y1-receptor actions to cumulative concentrations of 
[Leu31Pro34]NPY did not differ with respect to estrogen status (Figure 9: F (2, 13) = 
0.84, p = 0.45; D2 = 0.46). 
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Figure 9.  Cumulative concentration response curve 
for Y1-receptor agonist.  NPY-mediated 
vasoconstriction was similar in OVX (n = 7) and OVE 
(n = 9) rats.  Bars indicate mean ± S.E.M.
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Series 3: NPY potentiation of adrenergic vasoconstriction 
 NPY potentiates norepinephrine-mediated vasoconstriction through Y1-receptor 
activation.  This series was performed to assess the effects of estrogen on this Y1-
dependent mechanism.  OVE (n = 12) did not differ from OVX (n = 13) in 
norepinephrine-stimulated vasoconstriction (Figure 10: F (2, 22) = 0.19, p = 0.83; D2 = 
0.06).  Interestingly, neither OVE (n = 11) nor OVX (n = 10) exhibited NPY potentiation 
of norepinephrine-stimulated vasoconstriction (Figures 11: F (2, 18) = 1.23, p = 0.32; D2 
= 0.49). 
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Figure 10.  Cumulative concentration response 
curve for α-adrenergic-receptor agonist.  
Norepinephrine-mediated vasoconstriction was similar 
in OVX (n = 13) and OVE (n = 12) rats.  Bars indicate 
mean ± S.E.M.
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Figure 11.  Cumulative concentration response 
curve for NPY ([Leu31Pro34]NPY) potentiation of 
α-adrenergic-receptor agonist in OVX (A: n = 10) 
and OVE rats (B: n = 11).  NPY failed to potentiate 
norepinephrine-mediated vasoconstriction in OVX and 
OVE rats.  Bars indicate mean ± S.E.M.
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Series 4: DPPIV activity in gastrocnemius first-order arterioles 
 The enzymatic breakdown of NPY can impact the physiological response as only 
the full-length peptide stimulates vasoconstriction.  The DPPIV inhibitor, diprotin A, was 
added to the vessel bath to determine the effects of DPPIV activity on NPY 
bioavailability according to estrogen status.  DPPIV inhibition resulted in an increase in 
NPY bioavailability at 0s and 30s following field stimulation in OVX (n = 12) and OVE 
(n = 11) rats (Figure 12; F (3, 19) = 4.74, p < 0.05); however, there were no differences 
across groups (F (3, 19) = 1.10, p = 0.37, D2 = 0.74). 
 Whole vessel homogenates were analyzed to directly assess DPPIV activity.  
DPPIV activity (Figure 13: F (1, 26) = 0.01, p = 0.94, d = 0.03) did not differ between 
OVX (n = 13) and OVE rats (n = 15).  Follow-up protein assay was unable to determine 
differences in total vascular protein of OVX (n = 9) and OVE (n = 9) vessels (see 
Limitations).  DPPIV activity was similar between groups and the proteolytic actions of 
DPPIV played an integral role in modulating the bioavailability of NPY regardless of 
estrogen status in this young-adult cohort. 
 
 
 
 
 
 
 
 
 55 
 
Figure 12.  Effects of DPPIV inhibition on NPY release in gastrocnemius
first-order arterioles of OVX (n = 12) and OVE (n = 11) rats.  NPY 
release was greater with DPPIV inhibition (diprotin A) at 0s and 30s 
following field stimulation for all rats regardless of estrogen status.  Bars 
indicate mean ± S.E.M.  * Significant difference from control conditions (0s 
and 30s, respectively; p < 0.05).
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Figure 13.  DPPIV activity of OVX (n = 13) and 
OVE (n = 15) first-order arterioles. Estrogen 
supplementation did not influence DPPIV activity.  
Bars indicate mean ± S.E.M.
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Discussion 
NPY Vasoconstriction 
 The efficacy of NPY as a vasoconstrictor depends on the level (artery, arteriole) 
and location (mesentery, brain, skeletal muscle) of the vasculature under study.  Very 
little is known as to the behavior of NPY in the skeletal muscle arterioles of females.  
Prior study (Joshua, 1991) of male skeletal muscle arterioles revealed an inverse 
relationship between the magnitude of vasoconstriction (vessel diameter changes) and 
vessel size (first-, second-, third-order arterioles).  The amount of vasoconstriction 
observed in female skeletal muscle first-order arterioles was similar to previous 
measurements of the same vessel type observed in males (Joshua, 1991).  The 
cornerstone of the study was the long-term effect of estrogen on NPY neurotransmission.  
The available studies on sex-differences (Jackson, et al., 2005a, 2005b) in NPY 
neurotransmission have suggested that sex hormone status is a likely cause underlying the 
differences between males and females.  The present data fail to support a link with 
respect to estrogen and Y1-receptor activity as there were no differences between OVX 
and OVE groups.  While the null hypothesis was not rejected, the results further 
demonstrate the complexities involved in identifying the factors of influence behind the 
sex-differences in vascular physiology. 
 An absence of an estrogen effect is not unprecedented with similar null results 
having been observed in adrenergic neurotransmission.  Stice et al. (2009) observed no 
differences in adrenergic responsiveness in female aortas of OVE and OVX rats.  The 
aortas of rats without estrogen possessed greater contractile force (developed tension) 
than rats with estrogen, but the receptor responsiveness according to the adrenergic dose-
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response curve did not differ between groups.  Females with compromised estrogen 
profiles may experience vascular smooth muscle thickening (Moreau, et al., 2002; 
Takahashi, et al., 2004), which is a common clinical sign for increased risk of 
cardiovascular disease.  The nature of microvessel diameter measurement does not allow 
for an inference as to the amount of contractile force a vessel possesses; therefore, it was 
unknown if OVX vessels possessed greater contractile force.  Y1-receptor protein was not 
quantified during the present study; thus, it is unknown if either of the groups 
experienced a change in receptor protein with a concurrent change in receptor sensitivity.  
A recent study by Jackson, Ellis, and Shoemaker (2010) detected estrogen-related 
differences in Y1-receptor expression in white vastus muscle of young mature (2mo) 
female rats.  The increase in post-junctional receptor expression in rats without estrogen 
was in conjunction with changes in hemodynamics of conduit vessels (external iliac 
artery) in response to Y1-receptor blockade.  However, there was a nonsignificant 
increase in Y1-receptor in red vastus of rats with estrogen.  These equivocal results may 
suggest that differences in Y1-receptor actions may occur in response to changes in 
estrogen status, but these changes may be predicated on the type of muscle (red or white) 
tissue and corresponding blood vessels under study.  The present results would support a 
part of this concept in that Y1-receptor actions were identical in the red first-order 
arterioles of young adult females irrespective of estrogen status.  It was concluded that 
NPY can induce a moderate amount of vasoconstriction in isolated first-order arterioles 
of young adult females, and estrogen does not impact Y1-receptor sensitivity in these 
vessels. 
NPY Potentiation of Adrenergic Vasoconstriction 
 59 
 
 Neuropeptide Y is well known for its ability to potentiate norepinephrine-induced 
vasoconstriction at low concentrations (10-7 – 10-9 M) (Abel & Han, 1989; Han, et al., 
1998; Vu, et al., 1989).  The type of potentiation can refer to augmentation of the 
vascular response (vasoconstriction, increases in perfusion pressure) achieved following a 
neural stimulus (Glenn & Duckles, 1994; Han, et al., 1998), or it can refer to a leftward 
shift in the dose-response curve of norepinephrine indicating a greater sensitivity to 
norepinephrine (Abel & Han, 1989).  The ability of NPY to potentiate any facet of 
adrenergic vasoconstriction may depend on other factors such as vessel type and sex.  In 
the present study, OVX and OVE groups experienced a nonsignificant increase to 
norepinephrine-mediated vasoconstriction following NPY administration.  The 
concentration used, 9.8 X 10-8 M, is within the previously mentioned range of 
concentrations where NPY potentiates norepinephrine-mediated vasoconstriction.  
However, the vessels of both groups exhibited vasoconstriction to this concentration of 
NPY, which could have masked minor influences on adrenergic vasoconstriction. 
 There are many examples of NPY potentiation of norepinephrine effects on 
perfusion pressure of whole systems such as the mesentery (Han, et al., 1998; Westfall, et 
al., 1988).  Arterial beds provide a story as to a particular vascular system.  However, the 
potentiation cannot be accurately ascribed to any particular level within the system since 
the pressure changes represent a collective response to the stimulus (norepinephrine, 
norepinephrine + NPY).  Isolated vessel techniques circumvent the aggregate actions of 
whole vascular beds to allow for careful examination at specific levels of the vasculature.  
Thus, while potentiation may occur in some levels of the vasculature, it does not appear 
to occur in skeletal muscle first-order arterioles. 
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 The existence of multiple pathways for NPY-mediated vasoconstriction may 
explain the lack of potentiation in norepinephrine vasoconstriction.  NPY can influence 
both potassium and calcium flux via the inhibition of cAMP (Lobaugh & Blackshear, 
1990) and the production of IP3 (Duckles & Buxton, 1994), respectively.  Norepinephrine 
stimulates vasoconstriction through the production of IP3; therefore, the absence of NPY 
potentiation of norepinephrine would support the assertion that NPY does not cause a 
meaningful increase of IP3 in skeletal muscle arterioles.  This is consistent with other 
studies of arterioles that failed to observe a difference in vasoconstriction following the 
inhibition of cAMP production (Andriantsitohaina, et al., 1990).  It is certainly possible 
that the ability of NPY to potentiate the effect of norepinephrine is dependent on vessel 
size as some larger vessels experience increases in IP3 production following NPY 
administration (Duckles & Buxton, 1994).  It was surmised based on the present results 
that the cAMP inhibitory mechanism is the predominant mechanism through which NPY-
mediated vasoconstriction occurs in skeletal muscle arterioles of females, and that NPY 
does not elicit a meaningful amount of IP3 production to potentiate the vasoconstriction 
of norepinephrine.  The similarity of response to NPY in animals with and without 
estrogen suggests that the Y1-receptor mechanism was not influenced by estrogen 
supplementation.  NPY was a potent vasoconstrictor of skeletal muscle arterioles in both 
groups, but it does not affect the vascular response to norepinephrine. 
NPY Release 
 There is little information, if any, pertaining to NPY release from skeletal muscle 
arterioles.  Previous studies of whole skeletal muscle and conduit arteries have detected 
sex differences in total NPY content of the respective tissues.  It has been speculated that 
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estrogen could contribute to a portion of the differences observed between males and 
females.  In the present study, chronic estrogen supplementation did not affect NPY 
release at 0 or 30 seconds following field stimulation.  These data suggest that chronic 
estrogen does not influence NPY release in skeletal muscle first-order arterioles of young 
adult females. 
  Estrogen affects the expression of many vascular proteins (Miller & Duckles, 
2008); therefore, it was plausible that estrogen was an underlying mechanism behind the 
sex differences observed in total NPY content of various tissues.  A follow-up study into 
the effects of estrogen supplementation on NPY metabolism by Jackson et al. (2010) 
concluded that rats with estrogen had less NPY content in red and white vastus muscles.  
The differing results between the present study and the study by Jackson et al. could be 
attributed to several factors.  First, whole muscle homogenate does not discriminate 
between vessel type (arteries, veins, capillaries, venues); thus, it is difficult to pin down 
the source behind the differences in NPY content.  Whole muscle homogenate will also 
include blood elements that contain NPY originating from monaural sources (platelets, 
adrenal gland).  These sources may be sensitive to estrogen supplementation, which could 
affect the expression of NPY.  The present study possesses experimental control for 
extraneous sources of NPY such as those related to blood elements.  Therefore, the NPY 
content recorded is indicative of the NPY release characteristic of an isolated, skeletal 
muscle first-order arteriole, which appears to be independent of estrogen influence. 
 While this study was not directly concerned with age, age-related physiological 
issues in females often encompass dysfunctional release of sex steroids.  Recent work by 
Di Carlo et al. (2007) discovered increases in NPY content of human uterine arteries that 
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correlated with the different phases of menopause (pre- and post-menopause).  These data 
require a broader context for interpretation as other hormones (progesterone) may also 
influence vascular NPY content.  Ageing, as it relates to vascular physiology, also affects 
multiple aspects of the vasculature that involve alterations in function to both the 
endothelium and the vascular smooth muscle (Glenn & Duckles, 1994; Kitlinska, Lee, 
Movafagh, Pons, & Zukowska, 2002).  The present finding indicates that estrogen, in and 
of itself, does not contribute to a change in NPY release in isolated, skeletal muscle first-
order arterioles. 
DPPIV Activity 
 The actions of DPPIV can significantly impact the type and magnitude of 
response initiated by NPY.  Glenn et al. (1997) was one of the first to detect differences 
in vasoconstriction during peptidase inhibition between sham and ovariectomized 
females.  An elegant study by Jackson et al. (2005) proposed that females possessed a 
greater level of proteolytic activity than males in order to depress Y1-receptor-mediated 
vasoconstriction.  Thus, the hypothesis for estrogen’s involvement in the attenuation of 
NPY-mediated vasoconstriction was developed.  The present findings fail to support a 
link between estrogen and NPY metabolism in skeletal muscle arterioles.  While no effect 
was observed with estrogen supplementation, the results do reveal some interesting 
developments in our concept of NPY in the vasculature. 
 DPPIV activity plays a significant role in mitigating NPY availability in 
resistance vessels of young adult females regardless of estrogen status.  The physiological 
significance of an augmented role for DPPIV in the female resistance vasculature is that 
females would have less Y1-receptor actions, ergo less NPY-mediated vasoconstriction.  
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Systemic blood pressure is maintained, in part, through the actions of arterioles, which 
control blood flow into the capillary beds (Segal, 2005).  While it is difficult to determine 
the meaningfulness of DPPIV activity in influencing blood flow through the resistance 
vasculature, the present results do suggest a significant role for DPPIV in modulating the 
amount of available NPY. 
 The stark similarities of DPPIV activity through direct (enzymatic assay) and 
indirect (NPY assay following DPPIV inhibition) measurements provide evidence to 
support the idea that estrogen does not affect DPPIV mechanisms in first-order arterioles.  
Jackson et al. (2010) detected no difference in DPPIV activity with estrogen 
supplementation in whole tissue homogenate of red and white vastus muscles.  The 
strength of the present study was the DPPIV analysis of isolated first-order arterioles.  
Thus, DPPIV activity is independent of estrogen influences, and it is active in modulating 
NPY in first-order arterioles of young adult females. 
Practical Implications  
 The release and metabolism of NPY can have far reaching effects; thus, it is 
prudent to understand how and under what circumstances these mechanisms associated 
with NPY metabolism change in the vasculature.  A practical concern relevant to 
cardiovascular health is the increase in blood pressure that accompanies the ageing 
process (Narkiewicz, et al., 2005; Ng, Callister, Johnson, & Seals, 1993).  This is a 
multifaceted issue consisting of alterations in neurotransmitter release, receptor 
expression on the vascular smooth muscle, vascular smooth muscle cell proliferation, and 
endothelial cell function, to name a few.  The estrogen-independent conclusions of the 
present study are not unprecedented.  Stice et al. (2009) failed to detect estrogen-related 
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differences in adrenergic vasoconstriction; however, there were differences with age.  
Aged females were more sensitive to adrenergic agonists (phenylephrine) as compared to 
young adult females irrespective of estrogen status.  It should be noted that both young 
and old females without estrogen generated greater amounts of tension as compared to 
young and old females without estrogen.  A greater amount of vascular tension can be a 
function of vascular smooth muscle cell proliferation.  As stated above, vessel tension 
cannot be extrapolated from vessel diameter.  The inability to measure vessel tension 
along with the inconclusive measurements of total vascular protein makes it difficult to 
ascertain whether estrogen status influenced vascular smooth cell growth in the present 
study.  It is plausible, however, that estrogen-related differences in blood pressure with 
age are actually a product of small increases in vascular smooth muscle cell proliferation 
as opposed to increases in receptor actions of sympathetic neurotransmitters such as 
NPY. 
 Correlations between NPY content and menopause status have been observed in 
human uterine arteries.  Menopause marks an onset of dysfunctional release of sex 
steroids (estrogen, progestogen).  It is because of these interrelationships that sex 
steroids, specifically estrogen, are believed to be crucial in modulating NPY metabolism.  
The absence of an estrogen effect in the present study would run counter to an estrogen-
specific response on NPY metabolism.  Perhaps the previous relationships between 
hypoestrogenism and NPY content is dependent on progesterone or possibly on 
synergistic effects requiring both sex steroids.  Another caveat in the study of sex steroid 
influence in ‘intact’ females lies in the enzymatic milieu and form of estrogen present.  
Some vascular smooth muscle cells express steroid enzymes such as sulfatases and 
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sulfotransferases, which affect the amount of estrogen in conjugated form (Nakamura, et 
al., 2003).  These enzymes in addition to 17β-hydroxysteroid dehydrogenase-1 can affect 
the overall estrogen profile.  This profile necessitates careful consideration due to the 
variable potency of the different forms (estrone, estradiol) of estrogen in the vasculature.  
It is important to elucidate the underlying mechanisms behind menopause and NPY 
expression to expand our knowledge into factors related to ageing in females. 
 NPY is also an angiogenic peptide (Zukowska-Grojec, et al., 1998) with growth 
factor capabilities that are equivalent to that seen with vascular endothelial growth factor 
under certain conditions (Kurimoto, et al., 2004).  The angiogenic form of NPY is 
primarily associated with its fragmented metabolites that express an affinity for Y2 and 
Y5 receptors, although the Y1 receptor also initiates angiogenic mechanisms as well 
(Movafagh, Hobson, Spiegel, Kleinman, & Zukowska, 2006).  Since DPPIV produces 
these truncated forms of NPY (NPY3-36), increased activity of this enzyme at the local 
vascular level could produce pro-angiogenic processes.  Therefore, DPPIV has a dual role 
in NPY metabolism by decreasing the amount of vasoconstrictive NPY while 
concurrently increasing the amount of pro-angiogenic NPY.  This action could result in 
both beneficial and deleterious health effects.  On one hand, this function could serve to 
improve overall cardiovascular function by increasing the number of collateral branches 
from arterioles through angiogenesis and decreasing the amount of vasoconstriction via 
NPY mechanisms.  However, as a growth factor, increased proliferation of vascular 
smooth muscle cells could lead to changes in the tunica intima/media ratio under certain 
conditions, which is a risk factor for cardiovascular event. 
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 NPY and estrogen both possess pleiotropic actions in the vasculature.  It is this 
nature that necessitates thorough analysis from multiple angles in order to piece together 
possible interrelationships between NPY and estrogen.  Future studies should include 
progesterone supplementation in combination with estrogen to better mimic in vivo 
conditions, which would allow for the identification of possible synergistic effects 
between hormones.  Studies that include peptide/hormone expression (transcripts, 
prepro/prohormone) in addition to receptor expression along with subtypes would allow 
for a more comprehensive picture into sex steroid influences on NPY neurotransmission. 
Caveats 
 Ovariectomy of all animals was necessary to ensure experimental control over 
estrogen concentrations.  Surgery and long-term storage can create stress on the animals, 
which could affect normal physiology.  NPY release was elevated in both groups as 
compared to intact animals of the same age (unpublished data).  Therefore, caution 
should be used when comparing results from the present study to those found in intact 
females. 
 The age of animal selected (6 months) represents a young adult female (Turturro, 
et al., 1999).  While this was not an ageing study, some of the research into sex steroids 
and sympathetic neurotransmission utilize multiple age groups.  The present results 
suggest that long-term estrogen supplementation does not affect NPY release and 
degradation in young adult females.  However, the process of ageing may involve other 
mechanisms that, combined with estrogen, produce alterations in NPY metabolism that 
have been observed in other studies (Glenn & Duckles, 1994). 
Conclusions 
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 Long-term estrogen supplementation does not affect NPY metabolism in young 
adult females.  The Y1-receptor actions are uniform across estrogen and non-estrogen 
groups with maximal vasoconstriction approximately 55% of control diameter in skeletal 
muscle first-order arterioles.  Estrogen supplementation did not influence NPY release or 
DPPIV activity.  DPPIV plays an important role in attenuating the amount of bioavailable 
NPY in young adult females. 
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APPENDIX 
Data Analysis 
 The initial dissertation proposal called for a total of 30 rats (15 / group).  A total 
of 34 rats underwent surgery with half of those receiving the estrogen treatment.  While 
there were a sufficient number of animals for experimental purposes, not all of the 
animals were used in each experiment.  Reasons for animal exclusion on some 
experiments included equipment failure due to lab damage, drug costs (limited 
availability), and issues with vessel viability (for microvessel experiments).  Information 
relevant to specific series of experiments are listed below. 
 Model assumptions (α = 0.05) for both the univariate and multivariate case were 
considered for the respective statistical comparisons.  The assumption pertaining to 
independence of observations was addressed through uniform handling and storage of the 
animals.  Briefly, the animals were of the same strain (Fischer 344 rats) and were 
purchased from the same provider.  Animals were housed under 12:12 hour light:dark 
cycles, housed in the same facility and room, and consumed the same diet.  
Ovariectomized (OVX) and ovariectomized + estrogen (OVE) animals shared cages in 
order to minimize the possibility of ‘cage’ effects.  The previous steps were performed to 
ensure biological homogeneity with the exception being sex steroid profile, which was 
manipulated for experimental purposes.   
 Simple univariate descriptive statistics pertaining to distribution (Shapiro-Wilk, 
skewness, kurtosis) are provided for each dependent variable in addition to graphical 
representation (box-and-whisker plots).  The following sections provide information 
regarding the handling of data with regards to adherence to specific model assumptions.   
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Animal Characteristics 
 Plasma estradiol concentration.  Plasma estradiol was assayed for 11 rats 
(Figure A1: OVE [n = 6], OVX [n = 5]).  Estradiol was normally distributed (Table A1), 
and the variances were equal. 
 Body weight.  A total of 34 rats were ovariectomized with 17 rats receiving the 
estrogen treatment (Figure A2).  The body weights were normally distributed (Table A2), 
and the variances were equal. 
 Uterine weight.  The uterine weights were measured for all 34 rats.  The 
normality assumption did not hold due to a few extreme scores in an otherwise narrow 
distribution.  These extreme scores in both groups were attributed to surgical differences 
across rats.  Ovariectomy involves the removal of the ovaries, which requires two sutures 
for each ovary: one at the uterine horn and one at the adipose tissue on the other side of 
the uterine horn.  The uterine horn and ovary possess a significant amount of adiposity 
with a high degree of vascular supply to address.  Small openings are made in the 
surrounding adipose tissue to allow for careful suture of the uterine horn only with 
minimal adipose tissue involved.  A minimal amount of adipose tissue is desired when 
suturing as all tissue distal to the suture will become necrotic, so care is taken to prevent 
excessive amounts of necrosis.  All rats have varying amounts of fat to deal with in and 
around the reproductive organs, which influences the specific location of the suture 
around the ovary.  These small differences in suture location can affect the overall length 
of the uterine horn.  It was concluded that the small differences in suture location were 
responsible for the outliers seen in both groups, which caused the deviation away from a 
normal distribution.  Animals that comprised the outliers were removed from both groups 
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(OVX: # 22 (274 mg), # 27 (258 mg); OVE: # 2 (1330 mg), # 6 (1204 mg), # 12 (1174 
mg).  This addressed the normality assumption (Figure A3), but variances were not equal.  
In looking at the data and the magnitude of change in uterine weight with estrogen, it 
came as no surprise that the variances were not equal.  A decision was made to randomly 
select an observation from the group with the most observations (OVX: rat #31) and 
remove it from statistical consideration (Glass & Hopkins, 1996).  This step produced 
equal group sizes, which resulted in an analysis that was robust to the homogeneity of 
variances assumption (Glass & Hopkins, 1996). 
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Table A1 
Univariate Normality: Descriptive Statistics 
Variable Statistic OVE OVX 
Plasma Estradiol Concentration    
 Skewness 1.20 1.28 
 Kurtosis 1.30 2.89 
 Shapiro-Wilk 0.91 0.84 
Body Weight    
 Skewness -0.50 0.11 
 Kurtosis -0.55 0.03 
 Shapiro-Wilk 0.96 0.99 
Uterine Weight    
 Skewness -0.13 0.60 
 Kurtosis -1.01 -0.60 
 Shapiro-Wilk 0.94 0.93 
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Figure A1.  Plasma estradiol concentration box-
and-whisker plots for OVX (n = 5) and OVE (n = 
6) rats.
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Figure A2.  Body weight box-and-whisker plots for
OVX (n = 17) and OVE (n = 17) rats.
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Figure A3.  Uterine weight box-and-whisker plots 
for OVX (n = 14) and OVE (n = 14) rats.
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Cumulative Concentration Response Curves 
 The drug used to assess the activity of NPY’s post-junctional receptor, [Leu31-
Pro34]NPY, was in limited supply do to cost.  Therefore, a limited number of animals (N 
= 19) underwent cumulative concentration response curve testing for NPY with some 
observations excluded post hoc for various reasons (listed below).  The omnibus 
multivariate analysis of variance (F (6, 9) = 1.39, p = 0.32, D2 = 3.29) for the cumulative 
concentration response curves considered only complete observations, that is to say, only 
the observations that included the [Leu31Pro34]NPY experiments.  Since the omnibus 
MANOVA consisted of a low number of observations, post hoc MANOVAs were 
performed to include the observations where only norepinephrine or norepinephrine + 
NPY (NPY potentiation) curves were performed. 
 MANOVA requires similar assumptions to those associated with the univariate 
case.  Independence of observations was discussed above, which leaves the assumptions 
of multivariate normality and homogeneity of covariances to address.  Univariate 
normality does not ensure multivariate normality, but it is considered as a prerequisite for 
multivariate normality (Stevens, 2002).  Therefore, univariate normality was assessed for 
all observations.  While multivariate normality is an assumption for multivariate 
ANOVA, the effect on the alpha level for violation of this assumption may be negligible 
(Stevens, 2002).  The likelihood for violation of the homogeneity of covariances 
assumption increases with the number of variables included in the design.  However, the 
effects on alpha level with violations of this assumption are tempered when group sizes 
are similar (large to small: < 1.5) (Stevens, 2002). 
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 A cursory examination of the data revealed the presence of two influential 
outliers.  In the case of rat #16 (OVE), the vessel responded in an atypical fashion.  
Specifically, vasoconstriction following NPY or norepinephrine administration occurred 
at one concentration, which yielded high slope values.  This atypical response did not 
exclude the data by itself as there is always variability between vessels during dose 
response curves.  However, there were factors associated with the experimental 
preparation of this particular vessel that required consideration when interpreting the 
data.  Many of the vessels will have one or more collateral vessels, vessels that branch off 
of the arteriole, which require a suture in order to pressurize the vessel for experimental 
use.  Suturing the vessel is a trial-and-error process with additional sutures needed if 
leaks are detected during the equilibration period.  Moreover, the amount of branching 
differs between vessels, so some vessels require a great deal of attention (more sutures) 
during the preparatory phase of microvessel experimentation.  The vessel for rat #16 
required many sutures as there were many collateral branches to tie off.  Unfortunately, 
there were a number of leaks discovered during equilibration of this vessel, and the 
collateral branches were in a position that made tie-off difficult.  The leaks were 
successfully sutured, but the vessel was physically manipulated to a point where normal 
vascular response could have been compromised.  Following careful observation and 
consideration of the NPY and norepinephrine data, it was decided that this outlier 
occurred due to excessive manipulation of the vessel during experimentation.  The 
cumulative concentration response curve data from rat #16 was removed from analysis.  
The second outlier, rat #19 (OVX), had abnormally low resting vessel diameter values.  It 
was noted in the procedural notes that there were a number of bubbles present in the tips 
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of the vessel.  Bubbles near the entry ports of the vessel can interfere with the flow of 
albumin through the vessel.  This causes the vessel to collapse to a certain extent, which 
may potentially confound measurements of vascular response that utilize vessel diameter 
as the dependent variable.  As the percent of resting baseline values for this animal 
influenced the normal distribution of NPY and norepinephrine cumulative concentration 
response curves, it was decided that this outlier also occurred as a result of experimental 
manipulation and the data was subsequently removed from analysis (Table A2). 
 NPY cumulative concentration response curve.  The EC50 for rat #24 (OVE) 
was an outlier.  Graphpad software was able to obtain the curve fit; however, the curve 
possessed two concentrations that exhibited substantial responsiveness to NPY.  It was 
decided that a manual curve fit would capture a more accurate representation of the actual 
response to the drug, which in fact was the case (Graphpad fit: R2 = 0.97; manual fit: R2 = 
0.98).  The manual fit corrected the outlier, which produced a normal univariate 
distribution (Figure A4) for the EC50.  Rat #23 (OVE) failed to meet inclusion criteria 
(R2 > 0.90) and was summarily removed from analysis.  NPY slope (Figure A5) was 
normally distributed, and univariate variances were equal for EC50 and slope. 
 Norepinephrine cumulative concentration response curve.  The EC50 for 
norepinephrine was normally distributed for both groups (Figure A6).  The slope for 
OVE was normally distributed, but the slope for OVX failed to exhibit a normal 
distribution (Figure A7).  All observations were left in the analysis as no justification 
existed to warrant removal. 
 Norepinephrine + NPY cumulative concentration response curve.  EC50 for 
norepinephrine + NPY possessed a normal distribution for both groups (Figure A8).  
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Slope was normally distributed for OVX, but not for OVE (Figure A9).  Rat #14 (OVE) 
had a steep slope (outlier), but there was not sufficient evidence to remove it from 
analysis.  OVX rats #1, Blank, and 1B along with OVE rat # 2 did not undergo 
norepinephrine + NPY testing due to a shortage of [Leu31Pro34]NPY. 
 Effect sizes: meaningfulness of the differences.  The multivariate effect size for 
the omnibus MANOVA was large (D2 = 3.29), albeit statistically insignificant.  The 
omnibus MANOVA lacked power (< 0.80) to detect statistically significant differences 
due to the large number of dependent variables with a relatively small number of 
observations.  While the large effect size was intriguing, the post hoc MANOVAs for 
each drug (EC50 and slope), however, failed to further expose differences between the 
groups.  The moderate effect sizes observed in the NPY (D2 = 0.46) and NPY + 
norepinephrine (D2 = 0.46) cumulative concentration response curves would necessitate 
group sizes of approximately 40-50 observations to achieve reasonable statistical power 
(> 0.80) (Stevens, 2002).  The post hoc MANOVAs coupled with the graphical 
representation suggested that the groups were the same over the three cumulative 
concentration response curves. 
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Table A2 
Univariate Normality: Descriptive Statistics 
Variable Statistic OVE OVX 
NPY CCRC    
EC50    
 Skewness -1.01 0.59 
 Kurtosis -0.06 -1.32 
 Shapiro-Wilk 0.88 0.89 
Slope    
 Skewness -0.35 -0.20 
 Kurtosis -1.37 -0.96 
 Shapiro-Wilk 0.93 0.97 
NE CCRC    
EC50    
 Skewness -0.70 -0.64 
 Kurtosis -0.90 -0.25 
 Shapiro-Wilk 0.89 0.92 
Slope    
 Skewness -0.57 -0.55 
 Kurtosis -0.93 -1.55 
 Shapiro-Wilk 0.90 0.83 * 
NPY+NE CCRC    
EC50    
 Skewness -1.08 -0.28 
 Kurtosis 0.97 -1.63 
 Shapiro-Wilk 0.90 0.89 
Slope    
 Skewness -1.73 -0.94 
 Kurtosis 3.12 -0.42 
 Shapiro-Wilk 0.80 * 0.86 
*p < 0.05. 
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Figure A4.  N PY EC50 box-and-whisker plots for 
OVX (n = 7) and OVE (n = 9) rats.
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Figure A5.  NPY slope box-and-whisker plots for 
OVX (n = 7) and OVE (n = 9) rats.
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Figure A6.  Norepinephrine EC50 box-and-
whisker plots for OVX (n = 13) and OVE (n = 12) 
rats.
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Figure A7.  Norepinephrine slope box-and-whisker 
plots for OVX (n = 13) and OVE (n = 12) rats.
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Figure A8.  Norepinephrine + NPY EC50 box-and-
whisker plots for OVX (n = 10) and OVE (n = 11) 
rats.
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Figure A9.  Norepinephrine + NPY slope box-and-
whisker plots for OVX (n = 10) and OVE (n = 11) 
rats.
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NPY Release 
 A repeated measures design was used for the NPY release data.  The univariate 
case is a more powerful design when group sizes are small (Park, Cho, & Ki, 2009), and 
the assumptions are similar to the previous univariate assumptions with the exception of 
sphericity.  There will be some degree of violation of the sphericity assumption as it is a 
repeated measures design; thus, it would be expected to find correlations between 
dependent variables.  Severe violations can lead to inflated F values, and possibly, 
spurious conclusions.  Therefore, the Greenhouse-Geisser adjusted F-test was used to 
protect against type-I error. 
 It was noted during casual observation of the data that NPY release of both OVX 
and OVE groups was much higher than those observed in intact animals.  The 
significance of the high concentrations of NPY was that the assay had a maximum range 
of 10 ng ml-1, and the assay was most sensitive around 1 ng ml-1.  Some animals that were 
otherwise normal possessed NPY concentrations that were beyond the detectable range of 
the assay.  It was speculated that the higher concentrations of NPY were a product of the 
surgical procedure, long-term storage of the animals, or a combination of both. 
 Albino rats develop a reddish or pink appearance around their posterior neck and 
back during long-term storage.  It is believed that this color is associated with stress, 
which can be attributed to the close-quarters storage of the animals.  This coloring was 
not excessive, and there were no signs of abnormal behavior.  Animals were never kept in 
seclusion except following surgery (< 2 days), and the cage size was within acceptable 
guidelines for animals of this particular size.  Nevertheless, long-term storage could have 
played a role in the high NPY concentrations in both groups.  Another cause of the high 
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NPY concentrations could be due to the surgical procedure itself.  Surgery creates a stress 
on animals; thus, it would be plausible that a portion of the results were a product of the 
surgical procedure.  In either case, all animals received the same treatment, which 
preserved the veracity of the group comparisons.  However, some animals were excluded 
based off of NPY concentrations that exceeded the assay’s concentration range, or in 
cases where the vessel failed preliminary viability testing. 
 NPY release (Table A3) was normally distributed for OVX for all time points 
except the first (0 seconds).  OVX data (Figure A10) exhibited a tendency towards 
positive skewness with a flat distribution with the exception of the 3rd time point (0 
seconds with DPPIV inhibition), which was leptokurtic.  None of the measures of 
skewness or kurtosis were considered severe (> 2).  OVE data (Figure A11) failed to 
exhibit a normal distribution for the control time points (0 and 30 seconds) as well as the 
first time point with DPPIV inhibition (0 seconds).  The distributions consisted of a few 
outliers that positively skewed the mean.  Another feature of the OVE data was the 
narrow distribution, especially with the control time points.  Rats #13 and #15 were 
responsible for the high degree of skewness observed in the OVE group.  However, there 
was nothing about these observations or animal characteristics that merited their removal 
from the analysis.  It was decided, based off a lack of evidence to justify their exclusion, 
that the observations from rats #13 and #15 should remain in the analysis.   
 Similar to the cumulative concentration response curves, there was insufficient 
power to detect statistically significant differences in NPY release between the groups.  It 
would require approximately 35-45 observations per group in order to possess reasonable 
statistical power (> 0.80) to detect true differences in NPY release (Stevens, 2002) with 
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the magnitude of effect present (D2 = 0.74).  While statistical power was limited in this 
analysis, the present results do not support a difference in NPY release with respect to 
estrogen status. 
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Table A3 
Univariate Normality: Descriptive Statistics 
Variable Statistic OVE OVX 
0 Seconds (Control)    
 Skewness 2.14 1.03 
 Kurtosis 4.08 -0.06 
 Shapiro-Wilk 0.66 * 0.85 * 
30 Seconds (Control)    
 Skewness 1.50 0.16 
 Kurtosis 3.08 -1.29 
 Shapiro-Wilk 0.83 * 0.92 
0 Seconds (DPPIV Inhibition)    
 Skewness 0.94 1.33 
 Kurtosis -0.28 1.56 
 Shapiro-Wilk 0.85 * 0.86 
30 Seconds (DPPIV Inhibition)    
 Skewness 0.60 0.28 
 Kurtosis -0.98 -1.32 
 Shapiro-Wilk 0.89 0.90 
*p < 0.05. 
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Figure A10.  NPY release box-and-whisker plots at 
control and DPPIV inhibition conditions (OVX: n 
= 12)
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Figure A11.  NPY release box-and-whisker plots at 
control and DPPIV inhibition conditions (OVE: n 
= 11)
0s 30s 0s 30s
0
2
4
6
8
DPPIV Inhibitor
N
PY
 R
el
ea
se
 (n
g 
m
l-1
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 92 
 
DPPIV Activity 
 Differences in DPPIV activity were assessed through one-way analysis of 
variance.  OVE and OVX were similar in distribution (Figure A12); however, the OVX 
group possessed two outliers, which adversely affected normality.  Rats #1 and Blank 
registered substantially lower DPPIV values as compared to the other rats within the 
group.  These differences were attributed to the homogenate composition (saline) of the 
first two samples, which likely influenced the catalytic rate of the enzyme.  These two 
observations were removed from analysis yielding normal distributions (Table A4) and 
equal variances. 
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Table A4 
Univariate Normality: Descriptive Statistics 
Variable Statistic OVE OVX 
DPPIV Activity    
 Skewness -0.43 0.60 
 Kurtosis 0.06 0.11 
 Shapiro-Wilk 0.97 0.96 
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Figure A12.  DPPIV activity of whole vessel 
homogenate (first-order arteriole) box-and-
whisker plots for OVX (n = 13)and OVE (n = 15) 
rats.
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